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Abstract 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endo-
proteinases that are associated with the tumourigenic process. MMPs can 
degrade almost all extracellular matrix and basement membrane components, 
promoting tumour invasion and metastasis. They can also regulate and modify 
host defence and immune mechanisms as well as normal cell function, and 
therefore excessive blockage or inhibition of all MMPs may not lead to a positive 
therapeutic outcome. Most clinical trials with MMP inhibitors (MMPIs) have 
yielded disappointing results, perhaps due to inappropriate study design or 
tumour staging, or to the lack of selectivity. Nonspecifi c or broad-spectrum 
MMPIs seemingly affect several members of the MMP family causing side effects 
during antitumour therapy because of disruption of numerous physiological or 
defensive processes.
Bisphosphonates were shown to be broad-spectrum inhibitors of MMPs 
inhibiting MMP-1, -2, -3, -8, -9, -12, -13 and -20 and this inhibition was 
found to involve cation chelation. Bisphosphonates were further shown to exert 
anti-metastatic, anti-invasive and cell adhesion-promoting properties, which 
may eventually prevent metastases not only in hard tissues but in soft tissues 
as well in a dose-dependent manner. Clodronate, at therapeutically attainable 
concentrations, dose-dependently inhibited directly the activity of catalytic 
domain of human recombinant MT1-MMP, reduced the activation of proMMP-
2 and downregulated the expression of MT1-MMP mRNA and protein 
production in MG-63 human osteosarcoma cells.
Two novel decapeptides, CTT1 and CTT2, were generated and characterized 
to target selectively and specifi cally gelatinases (MMP-2 and -9), inhibiting their 
gelatinase activities in several human carcinoma cell lines and in endothelial 
cells both in vitro and in vivo. Furthermore, CTT1 and CTT2 reduced tumour 
growth and increased survival in a mouse model. It is therefore to be hoped that 
these novel gelatinase-specifi c MMPIs will in the future open up a new era in the 
medical treatment of cancer. The pivotal role of MMPs in pathological conditions 
demonstrates that the MMPIs are still attractive for drug development. 
ABSTRACT
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1. Introduction 
Matrix metalloproteinases (MMPs) form an enzyme family capable of degrading 
almost all constituents of the extracellular matrix (ECM) and the basement 
membrane (BM). Recent studies have shown that the role of MMPs in cancer 
progression is much more complex than that derived from their direct degradative 
action on ECM and BM components (Egeblad and Werb 2002, Freije et al. 
2003, Hojilla et al. 2003). MMPs can also regulate multiple cellular functions 
including cell growth, apoptosis, angiogenesis, invasion, metastasis and immune 
response by cleaving growth factor-precursors, cell adhesion molecules and 
other bioactive proteins including MMPs themselves. The MMP family includes 
collagenases, gelatinases, stromelysins, membrane-type MMPs (MT-MMPs) and 
other MMPs. Pathologically excessive expression of MMPs has been implicated 
in the processes of tumour growth, invasion and metastasis (Egeblad and Werb 
2002).
Over the past 20 years, the pharmaceutical industry has made extensive 
efforts to develop synthetic matrix metalloproteinase inhibitors (MMPIs) for 
the treatment of cancer and other tissue-destructive diseases (Baker et al. 2002). 
Most of the early anti-MMP drugs were designed as peptides mimicking of 
the collagen amino-acid sequence near the collagenase cleavage site, probably 
because at the time collagen degradation was viewed and regarded as a pivotal 
and key rate-limiting point during tumour growth and progression (Brown 
2000). It is now known that the diversity of MMP functions associated with 
cancer highlight the importance of protective activities of MMPs in tumour 
progression, an aspect that had seemingly been overlooked. Hence, it seems 
important to try to identify the physiological role of each individual MMP and 
its specifi c participation in the multiple and complex stages of tumour evolution 
in order to develop  effective and hopefully selective therapeutic interventions 
(Overall and Lopez-Otin 2002).
In this work, I studied the role of certain MMPs and MMPIs in tumour 
progression, but it should be kept in mind that these MMPs are not the only 
proteolytic contributors in these processes, and interactions between members of 
other classes of proteolytic enzymes, such as matrix destructive serine proteinases 
eventually provide additional complexity and regulation of proteolytic cascades 
associated with malignancies (Sorsa et al. 1997, Moilanen et al. 2003).
1.1. Structure of extracellular matrix (ECM) 
ECM forms complex, highly organized structures that provide support for 
both tissues and individual cells regulating their physical properties. ECM also 
regulates cell behaviour infl uencing their adhesion, migration, proliferation, 
shape, development and metabolic functions. The ECM is not a static structure, 
but rather constantly produced, remodelled and processed.
1. INTRODUCTION
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The ECM contains collagens, non-collagenous glycoproteins and 
proteoglycans. These structural macromolecules are largely secreted by fi broblasts. 
In more specialized tissues, such as bone and cartilage, the extracellular matrix is 
secreted by mesenchymal cells, such as chondroblasts in cartilage and osteoblasts 
in bone. The long collagen fi bres strengthen and organize the matrix, while the 
polysaccharides of the proteoglycans form an aqueous phase, which permits the 
diffusion of nutrients, metabolites and hormones between tissue compartments. 
Elastin, fi bronectin and laminin are among the major components of the ECM. 
Fibronectin is widely distributed in connective tissues, whereas laminin is found 
exclusively in the BM. Fibronectin is a large glycoprotein and has multiple 
domains, each with specifi c binding sites for other matrix macromolecules and 
for receptors on the surface of cells. It therefore contributes to both organizing 
the matrix and helping cells attach to it. Fibronectin is important not only for cell 
adhesion to the matrix but also for guiding cell migrations in vertebrate embryos 
(Alberts et al. 2002). Vitronectin, thrombospondin, tenascin, and SPARC 
(secreted protein, acidic and rich in cysteine) are other ECM glycoproteins.
The major proteins present in the ECM are collagens. To date, 30 different 
collagen α-chains differing in the primary sequence have been characterized, that 
are composed of three α-chains and contain at least one triple-helical domain of 
repeating glycines (Gly-X-Y motif). Insoluble collagen fi brils make up about 30% 
of the proteins in the human body (Aumailley and Gayraud 1998, Myllyharju 
and Kivirikko 2001). Fibrillar collagens (types I, II, III, V and XI) form fi brils 
and infl uence cellular functions through interactions with integrins and are the 
main collagen types found in connective tissue. Type I collagen is the most 
abundant protein in the human body and it is the major collagen in skin, bone, 
tendon and ligaments (Prockop and Kivirikko 1995).
1.1.1. Basement membranes
BMs are a 50- to 100-nm thick layer of highly specialized ECMs. They separate 
epithelial or endothelial cells from the adjacent connective tissue or surround 
groups of cells in e.g. fat, nerve and muscle tissue. BMs have highly specialized 
mechanical and biological functions. They provide physical support for tissues, 
serve as a physiological barrier for cells of different origin, regulate cell polarity 
and are involved in cell differentiation and migration as well as tissue repair and 
remodeling. BMs also act as reservoirs of plasma proteins, enzymes and growth 
factors (Yurchenco and O’Rear, 1994). Major BM components include type IV 
collagen, laminin, nidogen (entactin) and proteoglycans. Minor components 
include agrin, SPARC, fi bulins, type XV collagen and type XVIII collagen 
(Erickson and Couchman 2000, Ghohestani et al. 2001). Type IV collagen and 
laminin both exist as multiple isoforms, each forming a huge irregular network 
by self- assembly. These networks are connected by nidogen, which also binds to 
several other components (proteoglycans and fi bulins). BMs contain at least two 
kinds of proteoglycans, heparin sulfate proteoglycans and chondroitinsulfate 
proteoglycans. BMs are connected to cells by several receptors of the integrin 
family, which bind preferentially to laminins and collagen IV, and via some 
1. INTRODUCTION
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lectin-type interactions (Timpl and Brown 1996). Laminins are a family of at 
least 15 heterotrimeric glycoproteins composed of fi ve α, three β and three γ 
subunits. They are involved in many biological functions, such as regulation of 
tissue morphogenesis, cell differentiation, adhesion and migration (Colognato 
and Yurchenco 2000).
1.2. The functional and structural properties 
of matrix metalloproteinases (MMPs) 
Proteolytic enzymes are either exopeptidases, cleaving a substrate molecule’s 
terminal peptide bond, or endopeptidases, cleaving an internal peptide bond 
of the substrate. Endopeptidases are divided into serine, cysteine, aspartic and 
metalloproteinases based on their catalytic properties and inhibitor sensitivities 
(Stöcker et al. 1995). The urokinase type plasminogen activator (uPA), 
mentioned in this study, belongs to serine proteinases containing a serine residue 
in their catalytic site. UPA converts the plasma protein plasminogen into active 
plasmin, which has wide substrate specifi city and is able to activate several latent 
proMMPs (Silverman et al. 2001). 
To date, 24 different vertebrate MMPs have been identifi ed of which 23 are 
found in humans (Puente et al. 2003). MMPs are Ca2+ - and Zn2+ -dependent 
endopeptidases, that can collectively cleave most ECM and BM macromolecules 
(Table 1). MMP numbering is usually determined by the order of the discovery, 
MMP-1 being the fi rst. The MMPs share high protein sequence homology 
and have defi ned domain structures and thus, according to their structural 
properties, the MMPs are classifi ed as either secreted MMPs or membrane-
anchored MMPs, which are further divided into eight discrete subgroups: 
fi ve are secreted and three are membrane-type MMPs (MT-MMPs) (Fig. 1). 
MMPs consist of a single polypeptide, varying between 20-100 kDa in size. All 
MMPs are synthesized with a prodomain containing a leader sequence, which 
targets the protein for secretion. They are secreted as latent proforms, with a few 
exceptions of furin-processed family members MMP-11, MMP-23 and MMP-
28. The propeptide contains a conserved sequence PRCGXPD, in which the 
cysteine forms a covalent bond (cysteine switch) with the catalytic zinc (Zn2+) 
to maintain the latency of proMMPs. The catalytic domain contains the highly 
conserved zinc binding site HEBXHXBGBXHS motif, where H is histidine, E 
is glutamic acid, B is bulky hydrophobic amino acid, G is glycine, X is variable 
amino acid and S is serine in which zinc is coordinated by three histidines. The 
serine can also be replaced by threonine in certain MMPs, i.e. MMP-11 (Stöcker 
et al. 1995). The proline-rich hinge region links the catalytic domain to the 
hemopexin domain. The role of the hinge region in MMPs is unclear, but it has 
been reported that mutations in the MMP-8 hinge region affect autoproteolysis 
and substrate specifi city (Knäuper et al. 1997). The hemopexin domain is absent 
in MMP-7 (matrilysin) and MMP-26 (matrilysin-2, endometase). MMP-2 and 
MMP-9 (gelatinases A and B, respectively) contain three repeats of the fi bronectin-
type II domain inserted in the catalytic domain. MT1-, MT2-, MT3- and MT5-
MMP contain a transmembrane domain and MT4- and MT6-MMPs contain a 
1. INTRODUCTION
225239 Heikkila_2205.indd   Sec1:13 5/22/05   21:19:41
14
glycosylphosphatidylinositol (GPI) anchor in the C-terminus of the molecule, 
which attach these MMPs to the cell surface. MT-MMPs, MMP-11, MMP-23 
and MMP-28 contain a furin cleavage site (RXKR) between the propeptide 
and catalytic domain, making these proenzymes susceptible to activation by 
intracellular furin-convertases. MMP-23 contains an N-terminal signal anchor, 
which anchors proMMP-23 to the Golgi complex and has a different C-terminal 
domain instead of hemopexin-like domain (Fig. 1) (Sternlicht and Werb 2001). 
The secreted MMPs can also localized onto the cell surface by binding 
to integrins or to CD44, or through interactions with cell-surface-associated 
heparan sulphate proteoglycans, collagen type IV or the extracellular matrix 
metalloproteinase inducer (EMMPRIN) (Brooks et al. 1996, Yu and Stamenkovic 
1999, Sternlicht and Werb 2001).
1.2.1. Collagenases
The three mammalian collagenases are MMP-1 (collagenase-1), MMP-8 
(collagenase-2) and MMP-13 (collagenase-3), while collagenase-18 has been 
characterized from the frog. Collagenases cleave the native fi brillar collagens 
I, II, and III at a specifi c site three-fourths from the N-terminus. The cleavage 
takes place in a specifi c site between the glysine-isoleusine (Gly-Ile) of the α1 
chain and the glysine-leusine (Gly-Leu) residues of the α2 chain forming the 
characteristic αA (75%)- and αB (25%)- triple helical cleavage fragments that 
in body temperature denaturate into randomly coiled gelatin, being further 
degraded by other gelatinolytic MMPs and other proteinases (Birkedal-
Hansen et al. 1993, Sternlicht and Werb 2001). The collagenases differ in their 
substrate specifi cities and functional roles (Sorsa et al. 2004, Owen et al. 2004). 
MMP-1 preferably degrades collagen III, MMP-8 prefers type I collagen, and 
MMP-13 prefers collagen II (Birkedal-Hansen et al. 1993, Knäuper et al. 
1996a). Collagenases can also digest a number of other ECM and non-ECM 
molecules (Table 1). Furthermore, native triple helical type I and II collagens 
can be directly degraded by human tumour-associated trypsin-2 (Moilanen et al. 
2003, Stenman et al. 2004)
MMP-1 was the fi rst MMP found from the metamorphosing tadpole 
(Gross and Lapiere 1962). MMP-1 is expressed by fi broblasts, endothelial 
cells, macrophages, hepatocytes, chondrocytes, osteoblasts, tumour cells and 
migrating epidermal keratinocytes and its expression can be induced in certain 
infl ammatory diseases and cancers (Birkedal-Hansen et al. 1993, Meikle et al. 
1992, Giambernardi et al. 1998).
MMP-8 was fi rst cloned from messenger RNA (mRNA) extracted from the 
peripheral leucocytes of a patient with chronic granulocytic leukaemia (Hasty 
et al. 1987, 1990). MMP-8 is synthesized in polymorphonuclear leukocytes 
during their maturation in bone marrow and stored in specifi c intracellular 
granules, out of which it is secreted to the cell environment in response to 
external triggering stimuli (Hasty et al. 1987, 1990, Ding et al. 1997, 1996). 
MMP-8 can also be detected in mucosal fi broblasts, SCC cells of the tongue, 
chondrocytes, odontoblasts, monocyte/macrophages, melanoma cells, leukaemia 
cells, malignant plasma cells and human endothelial cells (Moilanen et al. 2003, 
1. INTRODUCTION
225239 Heikkila_2205.indd   Sec1:14 5/22/05   21:19:42
15
Cole et al. 1996, Palosaari et al. 2000, Giambernardi et al. 1998, Kim et al. 
2002, Wahlgren et al. 2001, Hanemaaijer et al. 1997, Kiili et al. 2002). MMP-8 
is expressed in vivo by bronchial epithelial cells and macrophages involved in 
bronchiectasis, oral SCCs, chondrocytes in rheumatoid arthritic and osteoarthritic 
lesions, rheumatoid synovial fi broblasts, in human gingival sulcular epithelial 
cells, in cells of human atheroma, in plasma cells associated with oral keratocysts 
and by cells in proliferating and migratory wound epithelia, in dermal fi broblasts 
and infl ammatory cells (Prikk et al. 2001, Moilanen et al. 2003, Chubinskaya 
et al. 1999, Hanemaaijer et al. 1997, Tervahartiala et al. 2000, Herman et al. 
2001, Wahlgren et al. 2001, Pirilä et al. 2001). ProMMP-8 can be activated by 
reactive oxygen species (Saari et al. 1990), human trypsin-2 (Moilanen et al. 
2003), MT1-MMP (Holopainen et al. 2003), MMP-3 (Knäuper et al. 1993) 
and bacterial proteases (Sorsa et al.  1992). 
MMP-13 was originally cloned from human breast tumour cDNA library 
(Freije et al. 1994). It has the widest substrate selection among the interstitial 
collagenases and, in addition to collagens, it is able to cleave various BM 
components.  MMP-13 cleaves type II collagen more effi ciently than type 
I and III, and among interstitial collagenases, it is most effective in cleaving 
gelatin (Mitchell et al. 1996, Lindy et al. 1997). The physiological expression 
of MMP-13 seems to be limited only to developing bone (Ståhle-Bäckdahl et 
al. 1997), wound healing and teeth (Ravanti et al. 1999, Pirilä et al. 2001, 
Sulkala et al. 2004). It is widely expressed in pathological conditions including 
rheumatoid arthritis, osteoarthritis, periodontitis, chronic ulcerations, SCC, 
hypertrophic chondrocytes, osteoblasts as well as plasma cells and many carcinoma 
and melanoma cells (Lindy et al. 1997, Vaalamo et al. 1997, Uitto et al. 1998, 
Johansson et al. 2000, Tervahartiala et al. 2000, Wahlgren et al. 2001, Mitchell 
et al. 1996, Johansson et al. 1997a, b, Giambernardi et al. 1998, Uria et al. 
1998, Bachmeier et al. 2000, Hofmann et al. 2000, Kiili et al. 2002). MMP-13 
is predicted to have an important role in tumour invasion and metastasis due to 
its wide substrate-specifi city together with catalytic effi ciency and its upregulated 
expression in cancer cells (Kähäri and Saarialho-Kere 1999).
1.2.2. Gelatinases
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) (also called type IV 
collagenases) are highly effi cient in cleaving gelatin along with type IV collagen 
and several other substrates (Table 1) (Birkedal-Hansen 1993). Gelatinases have 
been intensively studied in cancer and other diseases.
MMP-2 was the fi rst identifi ed type IV collagenase purifi ed from a malignant 
murine PMT sarcoma cell line and found to be a potent BM type IV collagen 
degrading enzyme (Salo et al. 1983). MMP-2 is typically expressed constitutively 
by various cell types, i.e. dermal fi broblasts, keratinocytes and endothelial cells 
(Birkedal-Hansen 1993), and its expression is associated with many different cell 
types and cancers, such as melanoma and fi brosarcoma (Huhtala et al. 1991) and 
can be observed in numerous cultured carcinoma cells (Giambernardi et al. 1998). 
Although MMP-2 null mice do not have any apparent abnormalities, mutations 
in MMP-2 cause bone resorption and arthritis, suggesting an important role for 
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MMP-2 in human osteogenesis (Martignetti et al. 2001). MMP-2 expression 
has been shown to relate to lymph node metastasis in oral SCC (Kusukawa et al. 
1993). In carcinomas, the MMP-2 is often derived from the surrounding stromal 
cells and not from tumour cells (Pyke et al. 1992, Soini et al. 1993). MMP-2 is 
involved in many processes that require ECM remodelling, and its overexpression 
is closely connected to cell migration and to the invasive and metastatic potential 
of malignant tumours (Visse and Nagase 2003, Giannelli et al. 1997).
MMP-9 was identifi ed as a gelatine-binding protein synthesized by human 
macrophages (Vartio et al. 1982), and the MMP-9 gene was cloned from the 
HT1080 fi brosarcoma cell line (Huhtala et al. 1991). The substrate specifi city 
of MMP-9 is very, but not completely, similar to MMP-2, although it does not 
degrade type I-III collagens as widely as MMP-2 (Table I). It is synthesized 
during late stages of PMN neutrophil development, stored within the tertiary 
granules and releases upon stimulus. In other cell types MMP-9 expression 
requires transcriptional activity (van den Steen et al. 2002). MMP-9 is expressed 
by keratinocytes, T-lymphocytes, alveolar macrophages, monocytes and plasma 
cells (Salo et al. 1991, 1994, van den Steen et al. 2002). MMP-9 plays an essential 
role in reproduction, growth and development, and its overexpression is also 
connected to the infl ammatory reaction, such as lung and periodontal diseases 
(Westerlund et al. 1996, van den Steen et al. 2002, Prikk et al. 2001, Westerlund 
et al. 1996). MMP-9 plays an important role in tumour cells, invasion and their 
metastatic potential (Stetler-Stevenson 1990, Giambernardi et al. 1998, Thomas 
et al. 2001, Vihinen and Kähäri 2002). 
MMP-2 and MMP-9 are in many respects highly similar enzymes, but 
signifi cant differences exist in the regulation of expression, glycosylation, 
proenzyme activation and substrate specifi cities. Despite their largely overlapping 
functions, MMP-2 and MMP-9 may even have opposing biological activity, as 
illustrated by the fi nding that MMP-2 promotes platelet aggregation, while 
MMP-9 inhibits the same process (Fernandez-Patron et al. 1999).
1.2.3. Stromelysins and stromelysin-like MMPs
MMP-3 (stromelysin-1) and MMP-10 (stromelysin-2) have similar substrate 
specifi cities, but MMP-3 exerts a higher proteolytic effi ciency than MMP-10 (Visse 
and Nagase 2003) (Table I). Stromelysin-3 (MMP-11) and human macrophage 
metalloelastase (MMP-12) are often included in a subgroup of stromelysin-like 
MMPs. MMP-3 and -10 are expressed by keratinocytes in vivo and fi broblasts in 
culture (Giambernardi et al. 1998, Johansson et al. 2000, Kähäri and Saarialho-
Kere 1999). MMP-11 is expressed in breast cancer, and it can degrade serine 
proteinase inhibitors (serpins) and α1-proteinase inhibitor, but not ECM 
components (Pei et al. 1994).
Metalloelastase (MMP-12) was initially found in alveolar macrophages of 
cigarette smokers (Shapiro et al. 1993). The expression of MMP-12 is also 
found in vivo in macrophages in granulomatous skin diseases, solar elastosis, 
in intestinal ulcerations and infl ammation (Vaalamo et al. 1998, Salmela et al. 
2001, Chung et al. 2002). MMP-12 is expressed in carcinoma cells of vulva and 
in skin cancers (Kerkelä et al. 2000). MMP-12 is able to cleave plasminogen into 
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angiostatin, thus preventing tumour growth by inhibiting angiogenesis (Dong 
et al. 1997, Cornelius et al. 1998).
1.2.4. Matrilysins 
MMP-7 (matrilysin-1) and MMP-26 (endometase/matrilysin-2) both lack the 
hinge region and hemopexin domains, which restricts their substrate specifi city 
(Table I). MMP-7 is produced by sweat and salivary glands, airway ciliated cells 
and the ductal or glandular epithelium of breast, liver, pancreas and urogenital 
tissues. MMP-7 is also expressed by malignant epithelial cells in tumours of the 
gastrointestinal tract, prostate and breast (Wilson and Matrisian 1996). Besides 
ECM components, MMP-7 processes cell surface molecules, pro-α-defensin, 
Fas-ligand, pro-tumour necrosis factor (TNF)-α and E-cadherin (Visse and 
Nagase 2003). 
MMP-26 was originally isolated from human endometrial tumour library. It 
is expressed in human placenta and uterus as well as in various tumour cells (Uria 
and Lopez-Otin 2000). MMP-26 also digests a number of ECM components 
and can activate proMMP-9 (Visse and Nagase 2003).
1.2.5. Membrane-type MMPs
The membrane-type MMPs contain six members, of which MT1-MMP 
(MMP-14), MT2-MMP (MMP-15), MT3-MMP (MMP-16) and MT5-MMP 
(MMP-24) are bound to the cell membrane with a transmembrane domain 
and contain a C-terminal cytosolic domain. MT4-MMP (MMP-17) and MT6-
MMP (MMP-25) are bound to the cell surface with a C-terminal hydrophobic 
extension that acts as a GPI anchor (Sternlicht and Werb 2001). MT-MMPs 
have a furin-sensitive RXKR motif between the propeptide and the catalytic 
domain, which is cleaved in trans-Golgi network leading to activation of MT-
MMPs (Sato et al. 1996). MT1-MMP was found on the surface of invasive lung 
cancer cells with the ability to activate proMMP-2 (Sato et al. 1994). MT-MMPs 
modulate cell-matrix interactions in cell invasion suggesting a marked role in 
tumour spread. MT1-MMP is expressed in various human cancers, including 
colon, head and neck carcinomas, liver metastases and hepatocellular carcinomas 
(Harada et al. 1998, Theret et al. 1998, Sato et al. 1994, Seiki et al. 1994). It has 
been identifi ed in both a membrane-associated and a shed soluble form in cultured 
breast cancer cells and fi broblasts as well as in the body’s infl ammatory exudates, 
(i.e. bronchoalveolar lavage fl uid, gingival crevicular fl uid and tear fl uid) (Li et 
al. 1998, Maisi et al. 2002, Tervahartiala et al. 2000, Holopainen et al. 2003). 
It is also expressed by skin fi broblasts (Madlener 1998, Okada et al. 1997) and 
endothelial cells (Silletti et al. 2001). Besides activating proMMP-2, -8 and -13, 
MT-MMPs can also degrade a variety of ECM molecules in vitro (Table 1) (Seiki 
et al. 1999, Holopainen et al. 2003, Knäuper et al. 1996b). 
1.2.6. Other MMPs
MMP-19 was cloned from the mammary gland (Cossins et al. 1996, Pendas 
et al. 1997). The protein is most similar to the stromelysin class of MMPs in 
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terms of activity. MMP-19 is expressed in several tissues, including placenta, 
lung, pancreas, ovary, spleen, intestine, thymus and prostate (Cossins et al. 
1996, Pendas et al. 1997b). In addition, it is expressed by capillary endothelial 
cells in acutely infl amed synovium, suggesting that MMP-19 can play a role in 
angiogenesis (Kolb et al. 1999). MMP-19 is strongly expressed in tumour cells 
and their surrounding vasculature in benign breast tumour, whereas progression 
towards invasive phenotype and neoplastic differentiation lead to disappearance 
of MMP-19 expression by these cells (Djonov et al. 2001). It can also have role 
in monocyte extravasation and subsequent infi ltration to tissue (Locati et al. 
2002). Human MMP-20 (enamelysin) was fi rst found in odontoblasts, and it is 
primarily located within newly formed tooth enamel (Bartlett et al. 1998). Later 
it was discovered in human tongue SCC cells, tooth pulp and placenta (Väänänen 
et al. 2001). MMP-20 can degrade amelogenin, the major component of the 
enamel matrix, laminin-5γ2 chain, aggregan and cartilage oligomeric matrix 
protein, but not fi brillar type I and II collagens (Table 1). The human MMP-21 
was characterized from human placenta cDNA. It is expressed in adult brain, 
lung, testis, ovary, colon and leukocytes as well as kidney along with several 
carcinoma cell lines (Ahokas et al. 2002).
The human MMP-23 lacks a signal peptide and the cysteine switch. By contrast, 
it does contain a short N-terminal signal-anchor that localizes MMP-23 to the 
cell membrane, and therefore represents the third subclass of membrane-bound 
MMPs (Pei 1999a). MMP-23 is activated and secreted by a single cleavage of 
an RRRR-motif in the trans-Golgi vesicles (Pei et al. 2000). Two copies of the 
MMP-23 genes are present in the short arm of chromosome 1, in a region that 
contains two identical genomic regions in a tail-to-tail confi guration. This region 
is thought to contain tumour suppressor genes (Gururajan et al. 1998). MMP-
23 is mainly expressed in ovary, testis and prostate, which suggests a specialized 
role in reproduction (Velasco et al. 1999). 
The MMP-28 (epilysin) is a recently cloned member of the human MMP 
family (Lohi et al. 2001) and is most closely related to MMP-19. MMP-28 is 
expressed by keratinocytes in the epidermis, and by developing germ cells in the 
testis. In addition, expression of MMP-28 is detected in the lung, heart, colon, 
intestine and brain (Lohi et al. 2001).
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Figure 1. Human MMPs structure based on their domain organization 
(modifi ed Sternlich and Werb 2001). PRE: predomain, PRO: propeptide, 
furin site, Zn2+binding site, Fi: fi bronectin type II inserts, hinge region, TM: 
transmembrane domain, Cy: cytoplasmic tail, GPI: glycosylphosphatidylinosit
ol domain, SA: signal anchor, CA: cysteine array, Ig-like: immunoglobulin-like 
domain.
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Table 1. Human MMPs and their substrates.
Enzyme                     Substrates 
MMP-1 (collagenase-1): aggrecan, collagens I-III, VII, X, XI, entactin, FN, gelatin, 
IGFBPs, Ln-1 link protein, myelibasic, tenascin, α1AC, α2M, α1PI, VN, casein, fi brin, 
fi brinogen, IL1α and -β, proTNFα, proMMP -1, -2, perlecan
MMP-2 (gelatinase A): aggrecan, collagens I, II-V, VII, X, XI, decorin, elastin, entactin, 
fi brillin, FN, fi bulins, gelatin, IGFBPs, Ln-1, -5, link protein, myelinbasic, osteonectin, 
tenascin, VN, fi brin, α1AC, α1PI, fi brinogen, IL1β, proTGFβ, proTNFα, plasminogen, 
substance P
MMP-3 (stromelysin-1): aggrecan, collagens III-V, VII, IX, X, XI, decorin, elastin, 
entactin, fi brillin, FN, gelatine, IGFBPs, Ln-1, link protein, myelinbasic, osteonectin, 
tenascin, VN, α1AC, α2M, α1PI, casein, fi brin, fi brinogen, IL1ß, proTNF-α, plasminogen, 
substance P, E-cadherin
MMP-7 (matrilysin): aggrecan, collagens I-III, entactin, fi brillin, FN, gelatin, Ln-1, -5, 
VN, α2M, α1PI, FVII, fi brin, fi brinogen, proMMP-2, proTNF-α,
MMP-8 (collagenase-2): aggrecan, collagen I-III, Ln-5, fi brinogen, substance P, α1PI, α2M
MMP-9 (gelatinase B): aggrecan, collagens IV, V, XI, XIV, decorin, elastin, fi brillin, 
gelatine, Ln-1, link protein, myelin basic, osteonectin, tenascin, VN, α2M, α1PI, casein, 
fi brin, fi brinogen, IL1β, proTGFβ, proTNFα, plasminogen, substance P
MMP-10 (stromelysin 2): aggrecan, collagens III-V, elastin, FN, gelatine, link protein, 
casein, fi brinogen, IGFBPs, α2M, α1PI
MMP-11 (stromelysin 3): aggrecan, collagens I, IV, elastin, entactin, fi brillin, FN, 
gelatine, Ln-1, myelin basic, vitronectin, α2M, α1PI, factor XII, fi brinogen, proTNF-α, 
plasminogen
MMP-12 (metalloelastase): aggrecan, collagens I, IV, decorin, elastin, entactin, FN, 
gelatin, Ln-1, link protein, myelin basic, osteonectin, tenascin, VN, α1PI, E-cadherin, 
fi brinogen, proTNFα, plasminogen, collagen IV, FN, gelatine, α1PI, fi brinogen
MMP-13 (collagenase 3): aggrecan, collagens I-IV,, VI, IX, X, XIV, fi brillin, FN, 
gelatine, Ln-1, -5, osteonectin, casein, FXII, α2M,fi brinogen
MMP-14 (MT1-MMP): fi brillin, FN, gelatin, proTNFα, collagen IV, FN gelatin, fi brin
MMP-15 (MT2-MMP): collagen 1
MMP-16 (MT3-MMP): collagens I, IV, FN, gelatin, tenascin, casein
MMP-17 (MT4-MMP): gelatin
MMP-18 collagenase 4): gelatin, casein
MMP-19: collagen II, gelatin, fi bronectin
MMP-20 (enamelysin): amelogenin, aggrecan, casein, gelatin, fi bronectin, type IV, XVIII 
collagens, laminin, tenascin C, COMP
MMP-23: gelatin
MMP-24 (MT5-MMP): proteoglycan, type I collagen, fi bronectin, laminin
MMP-25 (MT6-MMP): gelatin, type IV collagen, fi bronectin
MMP-26 (matrilysin 2, endometase): fi bronectin, fi brinogen, gelatin, type IV collagen, 
α1PI, laminin-1
MMP-27: type II collagen, gelatin, fi bronectin
MMP-28 (epilysin): casein
Modifi ed from and references from: Van den Steen et al. 2002, McCawley and Matrisian 
2001, Folgueras et al. 2004.
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1.2.7. The physiological functions of MMPs 
Embryonic growth and tissue morphogenesis are fundamental events that require 
disruption of ECM barriers to allow cell migration and microenvironmental 
matrix remodelling. The ability of MMPs to degrade structural components of 
ECM and BM has supported their direct roles in these processes (Vu and Werb 
2000).
Most MMP genes are highly expressed in a number of reproductive processes, 
including menstrual cycle, ovulation and uterine, breast and prostate involution 
(Curry and Osteen 2003, Hulboy et al. 1997). Thus, MMP-7, -3, -10 and -2 are 
consistently produced during the most active phases of the murine estrous cycle. 
These MMPs, as well as MMP-8 and MMP-13, are also up-regulated during 
postpartum uterus involution (Balbin et al 1998, Rudolph-Owen et al. 1997). 
In addition, the expression patterns of several MMP genes have been analysed 
during gonadotropin-induced ovulation in order to identify those members 
responsible for follicular wall degradation (Curry and Osteen 2003, Hagglund 
et al. 1999). However, none of the mutant mice defi cient in specifi c MMPs 
generated to date show signifi cant reproductive dysfunction. These fi nding 
suggests that functional redundancy among MMPs, or between these enzymes 
and components of the plasminogen system, may compensate for the loss of a 
specifi c MMP (Ny et al. 2002, Solberg et al. 2003). 
Studies with MMP-9-defi cient mice have demonstrated the in vivo role of 
this protease in a number of developmental processes. Thus, these mice exhibit 
a defect in endochondral bone formation, which is accompanied by delayed 
apoptosis of hypertrophic chondrocytes at the skeletal growth plates and defi cient 
vascularization (Vu et al. 1998). Targeted inactivation of the MT1-MMP gene in 
mice also causes several skeletal and connective tissue defects as well as defective 
angiogenesis leading to premature death (Holmbeck et al. 1999, Zhou et al. 
2000).
The role of MMPs in tissue remodelling has also been demonstrated in several 
reports. MMP-2 and MMP-3 regulate mammary gland branching morphogenesis 
during puberty (Wiseman et al. 2003). MMP-2 and MMP-9 also contribute to 
adipogenesis by promoting adipocyte differentiation (Bouloumie et al. 2001). 
However, other MMPs seem to have an inhibitory effect in this process. Thus 
MMP-3-defi cient mice show accelerated adipogenesis during mammary gland 
evolution (Alexander et al. 2001). MMPs are also involved in wound healing, a 
tissue-remodelling process which involves the migration of keratinocytes at the 
edge of the wound to re-epithelialize the damaged surface. Several studies in 
cell culture have shown that the proteolytic activity of MMP-1 is required for 
keratinocyte migration (Pilcher et al. 1997). The in vivo role of MMPs in this 
process has been supported by the analysis of MMP-3-defi cient mice, which exhibit 
impaired wound contraction (Bullardt et al. 1999), and by studies in MMP-1-
resistant mice that also show a severe delay in wound healing (Beare et al. 2003). 
However, the complete inhibition of the healing process requires the blockade of 
both plasminogen and MMP proteolytic activities, indicating again a functional 
overlap between both classes of matrix-degrading proteases (Lund et al. 1999). 
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The role of MMPs in angiogenesis is also wide and complex. Many MMPs 
are produced by endothelial cells and have been described to be important 
for the formation of new blood vessels in both physiological and pathological 
conditions. For example, MMP-2 associates with integrin αvβ3, and this 
interaction is essential for localizing the enzyme to the surface of newly forming 
vessels (Brooks et al. 1996). Further studies examining the links between 
MMP-2 and angiogenesis have shown that, after different challenges, MMP-2-
null mice show reduced vascularization compared to wild-type controls (Itoh et 
al. 1998, Lambert et al. 2003). The fi nding that choroidal neovascularization is 
severely impaired in MMP-2/MMP-9-double defi cient mice has demonstrated 
the synergic involvement of both proteases in this process (Lambert et al. 2003). 
In addition, enzymatic studies have revealed that the endogenous angiogenic 
inhibitor endostatin can block the activation or the catalytic activities of MMP-2, 
-9, -13 and MT1-MMP (Kim et al. 2000, Lee et al. 2002, Nyberg et al. 2003). 
MMPs may also regulate angiogenesis by acting as pericellular fi brinolysins 
during the neovascularization process (Hiraoka et al. 1998).
1.3. Regulation of MMPs
In order to avoid unwanted tissue damage it is crucial to accurately control the 
protease activity. The MMPs are tightly regulated, as they need to be present 
in the right cell type and pericellular location at the right time and in the right 
amount. A loss of activity control may result in diseases such as arthritis, cancer, 
atherosclerosis, aneurysms, nephritis, periodontal disease, tissue ulcers and 
fi brosis (Kähäri and Saarialho-Kere 1999).
MMPs are regulated both transcriptionally, including signal transduction 
from cell surface into nucleus, and post-transcriptionally, comprising modulation 
of mRNA half-life, secretion, localization and activation of proMMPs, as 
well as inhibition of active MMPs. MMP expression and activity seem only 
circumscribed under delicate control by their regulatory molecules to those sites 
and conditions in which proteolytic activity is necessary. However, malignant 
tumours have developed strategies to circumvent or overcome this regulatory 
mechanism to generate the uncontrolled and often pathologically excessive 
proteolytic activity associated with cancer development and metastasis (Nagase 
and Woessner 1999).
1.3.1. Transcriptional regulation of MMP genes
In normal tissues, MMPs are usually expressed at low levels but their production 
and activation is rapidly induced when active tissue remodelling or processing 
is needed. Most MMPs are closely regulated at the level of transcription, with 
the notable exception of MMP-2, which is often constitutively expressed and 
controlled through a unique mechanism of enzyme activation (Strongin et al. 
1995) and some degree of post-transcriptional mRNA stabilization (Overall et 
al. 2001). Furthermore, since they store preconstructed MMP-8 and MMP-9 
in specifi c and secretory granules, respectively, neutrophils can rapidly release 
or degranulate these MMPs if required (Weiss et al. 1989, Ding et al. 1997, 
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1996). In other cells, the expression of MMPs is induced or up-regulated in 
response to exogenous signals. Because the substrate specifi cities of distinct 
MMPs overlap, their biological function may also be determined by differential 
expression patterns. Otherwise, MMP gene expression is regulated by numerous 
stimulatory and suppressive factors that infl uence multiple signaling pathways, 
for example phorbol esters, integrin derived signals, extracellular matrix proteins, 
cell stress and contacts, and changes in cell shape (Curran and Murray 2000). 
MMP expression is regulated by several cytokines and growth factors, including 
interleukins, interferons, epidermal growth factor (EGF), keratinocyte growth 
factor (KGF), nervous growth factor (NGF), basic fi broblast growth factor 
(bFGF), vasculature endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF), tumour necrosis factor (TNF)-α, transforming growth factor 
(TGF)-β, and the extracellular matrix metalloproteinase inducer EMMPRIN 
(Curran and Murray 2000). These factors are typically released by the stromal 
cells, infi ltrating infl ammatory host defence cells or by tumour cells themselves. 
They activate transcription factors that recognize and bind to specifi c DNA 
sequences on the regulatory regions of genes. However, no single factor has been 
identifi ed that is exclusively responsible for the overexpression of MMPs specifi c 
for tumours, although tumour necrosis factor (TNF)-α and interleukin (IL)-1 
are often regarded to be implicated (Curran and Murray 2000). The same MMP 
can be transcriptionally induced or repressed by different agents, depending on 
the tumour-cell type. Some factors, such as TGF-β or retinoids, function as both 
positive and negative regulators of MMP transcription in normal and tumour 
cells (Overall et al 1989, Uria et al 1998, Overall 1995, Jimenez et al 2001). 
Extracellular stimuli affect MMP expression via signal transduction pathways 
like IL-1, TNF-α, PDGF, and EGF that lead to activation of AP-1 (activator 
protein-1) transcription factors. The expression of AP-1 transcription factors is 
induced by mitogen-activated protein kinase (MAPK) pathways, extracellular 
signal-regulated kinase (ERK 1, 2), stress activated proteinase kinase/Jun N-
terminal kinase (SAPK/ JNK) and p38. The AP-1 site is in the genes of MMPs-
1, -3, -7, -8, -9, -10, -12 and -13 at the proximal promoter approximately at 
-70 position from the transcription initiation site. MMP-1, -3 and -9 also have 
another AP-1 site in the distal promoters, but the role of this site is not clear. 
The MMP-2, -11, -28 and MT1-MMP genes do not have an AP-1 site. AP-1 
transcription factors regulate the expression of a variety of genes involved in 
proliferation, development, differentiation, infl ammation, stress response and 
tumour progression. AP-1 consists of members of the FOS and JUN family of 
oncoproteins, which could provide a general mechanism for the upregulation of 
MMP expression in malignant tumours. Several other nuclear factors control 
MMP expression and are likely to account for the variable inducibility of MMPs 
by several agents, or even by the same agents in different tumour-cell types. 
These include the ETS family of oncoproteins, which bind polyoma virus 
enhancer A binding protein 3 (PEA3) sites that are present in several MMP gene 
promoters (Curran and Murray 2000). AP-1 and ETS transcription factors can 
synergistically activate MMP gene transcription (Westermarck et al.1997). Their 
collaboration is also involved in the regulation of genes associated in tumour 
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progression (Denhardt 1996). Indeed, the expression of ETS-1 colocalizes 
with the expression of many MMPs at the invading edge of several types of 
tumours and in tumour vascularization (Bolon et al. 1995, 1996, Wernert et al. 
1994, 1992). Overexpression of ETS transcription factors enhances the activity 
of MMP-1, -3, and -9 promoters (Buttice et al. 1996, Gum et al. 1996, Kaya 
et al. 1996). Nuclear factor of κB (NF-κB) induces MMP-1, -3, -9, -13 and 
-14 (Bond et al. 1999, Han et al. 2001). Signal transducers and activators of 
transcription (STATs) mediate the effects of interferons (IFNs) on MMP gene 
expression (Ala-aho et al. 2000). T-cell factor 4 (TCF4) and CAS-associated zinc-
fi nger protein (CIZ) activate the expression of MMP-1, -3 and -7 (Crawford et al. 
2001, Nakamoto et al. 2000). P53 modulates the transcription of MMP-1, -2 and 
13 (Sun et al. 1999, 2000), and core-binding factor A1 (CBFA1) forms part of a 
regulatory cascade that controls MMP expression in both normal and tumour cells 
(Jimenez 2001). Negative regulatory elements, such as TGF-β inhibitory element 
(TIE) or AG-rich element (AGRE), have also been identifi ed in the promoters of 
several MMP genes (Kerr 1990, Benderdour 2002). The promoters of MMP-2, 
MT1-MMP and MMP-28 lack the common TATA boxes, but they contain target 
sequences for the Sp-1 transcription factor, which is commonly expressed in a variety 
of tissues and regulating many genes (Suske 1999). In addition, the promoters of 
MMP-3 and MMP-9 contain Sp-1 binding sites (Huhtala et al 1991). The Sp-1 
sequence is essential for the upregulation of MMP-9 transcription in cancer cells 
and in the promoter activity of MT1-MMP (Gum et al. 1996, Lohi et al. 2000). 
The promoter region of human MMP-13 contains an osteoblast-specifi c element 
2 (OSE2) that mediates the expression of osteoblastic-specifi c genes involving 
bone formation. Therefore, it could be involved in stimulating bone tumours or 
osteosarcomas (Ducy et al. 1997, Jimenez et al. 1999).  
Single-nucleotide polymorphisms present in the promoter of MMP genes 
create or abolish transcription-factor binding sites, thereby modifying MMP 
transcriptional activity. Specifi c MMP-1 and MMP-3 alleles have been associated 
with an increased susceptibility to several different types of cancer, including 
breast and ovarian carcinomas (Rutter et al. 1998, Biondi et al. 2000). 
Post-transcriptional mechanisms also modulate MMP expression. Examples 
include stabilization of MMP-1 and -13 mRNA transcripts by phorbol esters and 
EGF as well as stabilization of MMP-2 and -9 mRNA transcripts by TGF-β (van 
den Steen et al. 2002). The turnover of MMP-1 mRNA is apparently regulated 
by AU-rich sequences in the 3´-untranslated region, and similar sequences 
may also regulate the stability of other MMP transcripts (Sternlicht and Werb 
2001). MMP expression could also be regulated by alternative splicing. Multiple 
transcripts have been reported for MMP-8, -11, -13, -16, -17, -20, -25 and -26 
(Hu et al. 1999, Luo et al. 2002). Overall, it is clear that the transcriptional 
regulation of MMP production is a very complicated phenomenon including 
the regulation of the production and degradation of transcription factors and 
the regulation of their trans-activating activities and via these processes the 
modulation of MMP production in cells. 
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1.3.2. Activation of proMMPs
Most MMPs are secreted as latent, inactive proenzymes or zymogens, and 
their activity is controlled extracellularly by zymogen activation and inhibition. 
Cleavage by furin-like serine proteases can intracellularly activate proMMP-
11, -28, -23 and MT-MMPs in the Golgi apparatus before secretion as active 
enzymes (Pei and Weiss 1995). MMPs can be activated by proteinases or in vitro 
by conformational perturbants, such as thiol reagents, organomercurials, heavy 
metals (Hg and Au), detergents and oxidants (Nagase 1997). Low pH and heat 
treatment can also lead to activation. Certain serine proteinases, such as plasmin, 
chymotrypsin, cathepsin, trypsins, neutrophil elastase, kallikrein and mast cell 
tryptase, other MMPs, as well as bacterial and fungal proteases can also induce 
the activation pathway by a series of successive and/or single cleavages (Sorsa et 
al. 1992, 1997, Ding et al. 1995, Holopainen et al. 2003, Moilanen et al. 2003). 
The proMMPs latency is maintained by a cysteine switch, the interaction between 
cysteine residue and zinc ion. During activation the opening of the Cys-zinc bond 
allows zinc ion to react with H2O to maintain the stabilized open form of MMP, 
after which it still needs to pass through several structural changes to become fully 
active. MMP-9 has recently been detected to be active in binding to a substrate 
even its full-size proform, but the activation still needs the disengagement of 
the propeptide from the enzyme. This activation model is thought to take place 
via binding to a ligand or substrate (Bannikov et al. 2002). In vivo such full-
size activated MMP-9 species can be detected in periodontitis-affected gingival 
crevicular fl uid (Westerlund et al. 1996). In neutrophils, the proMMP-9 forms 
complex with integrin αMβ2 in intracellular granules, but after cellular activation it 
becomes localized to the cell surface (Stefanidakis  et al. 2004). 
Activation of proMMPs by plasmin is a relevant pathway in vivo. Plasmin is 
generated from plasminogen by tissue plasminogen activator bound to fi brin and 
by urokinase plasminogen activator bound to a specifi c cell surface receptor. Both 
plasminogen and urokinase plasminogen activator are membrane-associated, 
thereby creating localized proMMP activation and subsequent ECM turnover. 
Plasmin has been reported to activate proMMP-1, -3, -7, -9, -10 and -13 (Murphy 
and Grappe 1995). 
Activated MMPs can participate in processing other MMPs and interfere 
with fi ner regulatory mechanism (Lijnen 2001). MMP-3 is able to activate 
MMP-1, proMMP-2, MMP-8 and MMP-9. Active MMP-2 and MMP-13 can in 
collaboration activate proMMP-9, MMP-13 can be activated by MMP-2, MMP-
3 and MMP-10 (Knäuper et al. 1996b, D’Ortho et al. 1997, Cowell et al. 1998, 
Curran and Murray 2000, Deryugina et al. 2001, Holopainen et al. 2003). 
MMP-7 can activate proMMP-8 and -9 (Balbin et al. 1998, von Bredow et al. 
1998). Hence it is highly diffi cult to defi ne the initiator of the activation cascades 
as well as how the fi rst enzyme in the cascade is activated. One possibility is 
that some of the proenzymes are suffi ciently active of the initial cleavage for the 
matrix destructive serine proteinase human tumour-associated trypsin-2 to act 
as the fi rst initial proteolytic activator of proMMP-activation cascade (Sorsa et 
al. 1997, Moilanen et al. 2003). 
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The main activation of proMMP-2 takes place on the cell surface and is 
mediated by MT-MMPs including MT1-MMP, MT2-MMP, MT3-MMP, 
MT5-MMP and MT6-MMP. MT4-MMP does not activate proMMP-2 (Visse 
and Nagase 2003). 
MT1-MMP-mediated activation of proMMP-2 has been studied extensively. 
Activation of MMP-2 by MT1-MMPs involves TIMP-2. The N-terminal domain 
of TIMP-2 binds to and inhibits MT1-MMP, whereas the C-terminal domain of 
the same TIMP-2 molecule binds the hemopexin-like domain of MMP-2 forming 
a ternary complex. An adjacent TIMP-free MT1-MMP subsequently cleaves the 
MMP-2 to the intermediate 64-kDa form by cleaving the Asn37-Leu38 bond 
located in a readily accessible bait region between the fi rst and the second α 
helix of the prodomain. This intermediate form is then processed into the fully 
mature 62-kDa form through cleavage of the Asn80-Tyr81 bond by an already 
active MMP-2 molecule (Murphy and Grappe 1995, Strongin et al. 1995). Only 
the active MT1-MMP binds MMP-2 on the cell surface; regulation of MT1-
MMP activation is thus an important control point to regulate MMP-2 activity 
(Lehti et al. 1998). Although TIMP-2 is normally required for the MMP-2 
activation, higher TIMP-2 levels lead to inhibition of MMP-2 activation. On the 
other hand, soluble MT1-MMP activates MMP-2 with a high effi ciency in the 
absence of TIMP-2 (Pei and Weiss 1996). ProMMP-2 activation by MT2-MMP 
is direct and independent of TIMP-2 (Morrison et al. 2001). The cell surface 
activation of MMP-13 by MT1-MMP can be direct or enhanced with active 
MMP-2 (Knäuper et al. 1996b). MMP-8 can also be activated by MT1-MMP 
(Holopainen et al. 2003). Integrins are also involved in the activation process 
directly or indirectly, as αvβ3 and β1 integrin activating antibodies modulate 
MMP-2 activation (Yan et al. 2000).The direct involvement is supported by the 
fi nding that the intermediate active MMP-2 is capable of αvβ3 integrin binding, 
and this interaction could thus affect MMP-2 activation (Brooks et al. 1996, 
Deryugina et al. 2001).
1.4. Mechanisms of cancer growth, invasion and metastasis 
formation
The term cancer describes a heterogeneous group of more than 200 different 
types of malignant tumours (Clark 1991). In the year 2002, 23,283 people in 
Finland were diagnosed with cancer and 9,875 died from it in 2001(Finnish 
Cancer Registry). Mouth and pharynx cancer is the eight most common solid 
tumour in the world (Parkin et al. 1999). In Finland, 456 new cases were 
diagnosed in 2002, 106 of which were squamous cell carcinomas of the tongue 
(Finnish Cancer Registry). 
Tumour progression is a complex and multistage process in which normal 
cells undergo genetic alteration, lose their normal proliferative control and 
become able to invade and colonize surrounding tissue and eventually distant 
target organs. In most cases, a tumour shows a selective non-random pattern of 
metastasis to particular organs, depending on the site where the primary tumour 
occurs (Rusciano and Burger 1994, Fidler 1995).
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Benign epithelial tumours have an intact BM that separates the neoplastic 
epithelium from the stromal connective tissue, whereas malignant epithelial 
tumours have a defective BM that allows neoplastic cells to invade the underlying 
stroma (Barsky et al. 1983). The initial stage of tumour invasion is the loss of an 
intact BM. Tumour cell invasion through the BM is thought to be a three-step 
process. First, the neoplastic cells attach themselves to the underlying BM. Then 
the malignant cells produce proteolytic enzymes to degrade the BM. Finally, 
the tumour cells pass through the BM and spread into the adjacent connective 
tissue. The steps of attachment, degradation and invasion are repeated within 
the ECM during tumour growth and spread. A malignant tumour spreads to 
other parts of the body by fi rst invading through the wall of a blood vessel or 
a lymphatic vessel. The tumour cells then travel with the stream, attach to a 
distant location and degrade the BM and ECM at the site of the metastasis. The 
continued growth and survival of solid neoplasms requires angiogenesis, the 
growth of new blood vessels from pre-existing ones. Without new blood vessels 
to provide nutrients and remove waste, tumours would be unable to grow larger 
than 2-3 mm in diameter. Tumour-induced lymphangiogenesis also plays a role 
in tumour progression (Folkman 1995, Skobe et al. 2001).
The current view concerning the role of stromal component in tumour growth 
points out that stroma actually participates in tumour progression and that 
stromal fi broblasts and infl ammatory cells can cause tumourigenic conversion 
of epithelial cells. Evidence has also been provided for the interplay between 
tumour cells and the stroma from fi ndings that in the early stages of epithelial 
malignancy, when the basement membrane is still intact, angiogenesis is observed 
in stroma (Hanahan and Folkman 1996). Some studies have confi rmed that 
tumour can generate its own non-malignant stroma and that one function for 
this is the reciprocal interaction with epithelial tumour cells to facilitate tumour 
growth (Lewis et al. 2004, Petersen et al. 2003).
Using an immunocytochemistry assay (ICC), circulating tumour cells or 
micrometastases have been detected in almost half of head and neck cancer 
(HNC) patients (Wirtschafter et al. 2002). The clinical implications of circulating 
tumour cells in patients with HNC have not been completely clarifi ed. However, 
in the case of prostate cancer, the patients with circulating tumour cells have 
decreased disease-free and overall survival in comparison to patients without 
circulating cells (Wirtschafter et al. 2002). 
1.4.1. MMPs in cancer 
Originally, MMPs were considered to be almost exclusively important in invasion 
and metastasis of cancers. However, in addition to invasion, current MMP actions 
are known to contribute to multiple steps of tumour progression, including 
tumour growth, apoptosis, angiogenesis and spread and growth of metastatic 
lesions at distant organ sites. MMPs are not only synthesized by tumour cells 
but are also produced by surrounding stromal cells, including fi broblasts and 
infi ltrating infl ammatory cells. In addition to creating gaps in matrix barriers, 
MMPs can solubilize cell surface and matrix-bound factors that can act in an 
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autocrine or paracrine manner infl uencing cell growth, death and migration. In 
this regard MMPs have both cancer-promoting and cancer-inhibiting as well 
as anti-infl ammatory functions, and pathways with opposing effects on cancer 
progression are sometimes initiated by cleavage of the same substrate (Balbin et 
al. 2003, Andarawewa et al. 2003, Owen et al. 2004, Sorsa et al. 2004). The 
proposed roles of MMPs in these processes are based on both in vitro and in 
vivo preclinical studies as well as on studies of clinical tissue specimens (Overall 
and Lopez-Otin 2002). 
The development of an altered stromal microenvironment is a common feature 
of many tumours. There is increasing evidence that these stromal changes, which 
include increased focal expression of proteases, cytokines and growth factors, 
may actually promote tumour progression. A common fi nding is that stromal 
fi broblasts become activated myofi broblasts, expressing smooth muscle actin and 
secreting cytokines, growth factors, proteases and matrix proteins. In one study 
oral SCC cells and primary oral fi broblasts directly induced a myofi broblastic 
phenotype, and this transdifferentiation was found to be dependent on SCC-
derived TGF-β1. In turn, myofi broblasts secrete signifi cantly higher levels of 
hepatocyte growth factor/scatter factor compared to fi broblast controls, and 
this factor promotes SCC invasion through Matrigel, a mixture of basement 
membrane proteins (Lewis et al. 2004, Petersen et al. 2003). 
Figure 2. Schematic representation of the steps in tumour progression. MMPs 
have been implicated to play a role in most of these steps. Tumours contain in 
their stromal compartment non-malignant cells such as fi broblasts and immune/
infl ammatory cells, which may act as a source for MMPs and other molecules to 
nourish tumour development. 
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1.4.2. MMPs in tumour growth
There is increasing evidence supporting the participation of MMPs in the 
regulation of tumour growth by favouring the release of cell proliferation factors 
such as insulin-like growth factors that are bound to specifi c binding proteins 
(IGF-BPs) (Manes et al. 1997). MMPs may also target and activate growth 
factors whose precursors are anchored to the cell surface or sequestered in the 
peritumour ECM. For example, cell surface-localized MMP-9 proteolytically 
activates TGF-β promoting tumour growth, invasion and angiogenesis (Yu and 
Stamenkovic 2000). In contradiction, some investigators showed that MMPs 
might negatively regulate cancer cell growth by activating TGF-β. One key event 
that leads to TGF-β-induced growth arrest is the induction of expression of the 
CDK (cycline dependent kinase) inhibitors (Derynck et al. 2001). The expansion 
of tumour cells inside a three-dimensional collagen-matrix is signifi cantly 
enhanced in response to MT1-MMP overexpression. By contrast, overproduction 
of a number of soluble MMPs had no effect on tumour cell growth (Hotary et 
al. 2003). The ability of MT1-MMP to confer this proliferative advantage to 
tumour cells is not apparent when cells are placed in a two-dimensional system, 
confi rming the importance of physical presentation of the surrounding ECM on 
cell behaviour (Cukierman et al. 2001). In MMP-9-defi cient mice cancer cell 
proliferation was decreased in tumours compared with wild type mice (Coussens 
et al. 2000).
1.4.3. MMPs in apoptosis
The ability of MMPs to target substrates that infl uence the apoptotic process, 
positively or negatively, is also relevant for cancer. Thus, MMP-3 has pro-
apoptotic actions on the neighbouring epithelial cells (Witty et al. 1995), whereas 
MMP-7, which is able to release the membrane-bound Fas ligand (FasL), can 
also induce epithelial cell apoptosis (Powell et al. 1999). This cleavage can also 
favour tumour progression as a result of the protection that FasL confers to 
cancer cells from chemotherapeutic drug cytotoxicity (Mitsiades et al. 2001). 
Released FasL induces apoptosis of neighbouring cells, or decreases cancer cell 
apoptosis, depending on the system (Powell et al. 1999, Mitsiades et al. 2001). 
In this regard, mice defi cient in MMP-2, -3 or -9 have lower levels of apoptosis 
induced by TNF-α, suggesting that MMPIs may be useful in cancer therapies 
using infl ammatory cytokines (Wielockx et al. 2001). Other MMPs, such as 
MMP-11, suppress tumour cell apoptosis by inhibiting cancer cell death (Boulay 
et al. 2001). MMP-11-/- MMTV-ras transgenic mice develop more metastases 
than their MMP-11+/+ MMTV-ras counterparts, despite the lower number 
and size of primary tumours (Andarawewa et al. 2003). These data imply that 
in addition to its antiapoptotic action, MMP-11 may have another molecular 
function that leads to a decreased metastatic rate. MMPs are also part of the 
apoptotic process, for example cleaving E-cadhering and PECAM-1 during 
apoptosis of endothelial and epithelial cells (Ilan et al. 2001, Steinhusen et al. 
2001). These observations emphasize the importance of selectively targeting 
certain MMP functions instead of completely blocking their activity.
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1.4.4. MMPs in the infl ammatory reactions 
MMPs have traditionally been associated with the variety of escaping mechanisms 
that cancer cells develop to avoid host immune response (Coussens et al. 2000; 
Coussens and Werb 2002). Some MMPs, such as MMP-9, can suppress the 
proliferation of T lymphocytes through the disruption of IL-2Rα signalling 
(Sheu et al. 2001). Likewise, MMP-11 decreases the sensitivity of tumour cells 
to natural killer cells by generating a bioactive fragment from α1-proteinase 
inhibitor (Kataoka et al. 1999). In addition, MMPs may modulate antitumour 
immune reactions through their ability to effi ciently cleave several chemokines 
or regulate their mobilization (Li et al. 2002, McQuibban et al. 2000, van 
den Steen et al. 2002). However, MMPs are eventually benefi cial to the host 
by stimulating protective and adaptive immune responses. In this regard, a 
recent report has revealed that mutant male mice defi cient in MMP-8 exhibit 
an increased skin tumour susceptibility compared to wild-type mice (Balbin et 
al. 2003). Furthermore, MMP-8 expression was found to be under hormonal 
control. Male MMP-8 knock-out mice were more suspectible to cancer than 
ovaries removed female mice (Balbin et al. 2003). Histopathological analysis 
of these MMP-8-defi cient mice has revealed the presence of abnormalities in 
the infl ammatory response induced by carcinogens. In fact, the lack of MMP-8 
hampers the early stages of infl ammation, but once established it is abnormally 
sustained leading to a more favourable environment for tumour development. 
Infl ammatory cells, such as macrophages, neutrophils and mast cells, of a 
developing neoplasm facilitate genomic instability, promote angiogenesis and 
produce chemokines and cytokines that induce or inhibit MMP transcription 
or activation and can infl uence tumour development and its microenvironment 
(Coussens and Werb 2001, 2002). Therefore, and contrary to previous studies 
performed with mice lacking specifi c MMPs, loss of MMP-8 enhances rather 
than reduces tumour susceptibility (Balbin et al. 2003). A putative mechanism 
to explain these paradoxical or unexpected effects of a member of the MMP 
family comes from its potential proteolytic processing activity on infl ammatory 
mediators, which could contribute to the host antitumour defence system 
(Coussens and Werb 2002). 
1.4.5. MMPs in angiogenesis
The role of MMPs in angiogenesis is considered to be dual and complex. The 
relevance of MMPs as positive regulators of tumour angiogenesis has been largely 
demonstrated. Thus, several pro-angiogenic factors such as VEGF, bFGF or TGF-β 
are induced or activated by MMPs, triggering the angiogenic switch during 
carcinogenesis and facilitating vascular remodelling and neovascularization at 
distant sites (Belotti et al. 2003, Bergers et al. 2000, Mohan et al. 2000, Sounni 
et al. 2002, Yu and Stamenkovic 2000). MMPs might simply act by degrading 
the ECM, which would allow endothelial cells to invade the tumour stroma 
(Seandel et al. 2001). An additional connection between angiogenic factors 
and MMPs derives from the recent fi nding that MMP-9 is induced in tumour 
macrophages and endothelial cells to promote lung metastasis (Hiratsuka et al. 
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2002). Furthermore, MMP-9 contributes to the malignant behaviour of ovarian 
carcinomas by promoting neovascularization (Huang et al. 2002). However, 
and contrary to these proangiogenic roles of MMPs, the recent description 
of mechanisms by which MMPs can negatively regulate angiogenesis have 
contributed to enhance the functional complexity of this proteolytic system in 
cancer. Thus, a number of MMPs are able to cleave the precursors of angiostatin 
and endostatin, and generate the active forms of these endogenous angiogenesis 
inhibitors (Cornelius et al. 1998, Ferreras et al. 2000, Heljasvaara et al. 2005). 
Furthermore, a recent study has correlated the generation of tumstatin by MMP-
9-mediated proteolysis of type IV collagen with the suppression of pathological 
angiogenesis and tumour growth (Hamano et al. 2003).
1.4.6. MMPs in invasion and metastasis
The importance of MMPs in cancer cell invasion originated from the study by 
Liotta et al., who were the fi rst to show that metastatic properties of tumour 
cells correlate with the degradation of type IV collagen, the main collagenous 
component of the BM (Liotta et al. 1980). 
Overexpression of MMP-2, -3, -13 and -14 promotes, while overexpression of 
TIMPs inhibits the invasion of cancer cell lines through either collagen I, optic 
nerve explants or Matrigel (Ahonen et al. 1998, Lochter et al. 1997, Belien et al. 
1999, Deryugina et al. 1997, Ala-aho et al. 2002). In experimental metastasis 
assays, the number of colonies formed in the lungs of mice is reduced by MMP-9 
downregulation in cancer cells, and is also reduced in the MMP-2 and -9-null 
mice as compared with wild type mice (Hua and Muschel 1996, Itoh et al. 
1998, Itoh et al. 1999).  MMP-2, -14 and -13 can degrade laminin-5γ2-chain, 
another BM component, which plays an important role in epithelial cell motility 
(Giannelli et al. 1997, Koshikawa et al. 2000, Pirilä et al. 2003). The interaction 
of laminin-5 with α6β4 integrin leads to the assembly of hemidesmosomes that 
anchor epithelial cells to the underlying basement membranes (Baker et al. 1996). 
Epithelial cells may be stimulated to express MT1-MMP by environmental signals 
leading to activation of MMP-2 and cleavage of laminin-5γ2-chain further 
triggering epithelial cell migration through reconstituted basement membrane 
(Giannelli et al. 1997, Koshikawa et al. 2000, Pirilä et al. 2003). 
Interactions between tumour cells and matrix components are important 
for the growth and invasion of malignant tumours (Iozzo, 1995). During 
migration, which is the fi rst step in invasion, cancer cells must detach from both 
neighbouring cells and the surrounding matrix. Thus, migration is regulated 
by cycles of localized MMP activity, rather than by continuously high MMP 
activity. 
CD44 is a major hyaluronan receptor that is involved in cell-cell and cell-
matrix interactions. CD44 is cleaved by MMP-14 and the extracellular domain 
is released to stimulate migration of the pancreatic tumour cell line (Kajita 
et al. 2001). In addition to binding to the ECM, CD44 also binds MMP-9, 
thereby augmenting the enzyme localization to the cell surface. This localization 
is required for MMP-9 to promote tumour invasion and angiogenesis. CD44, 
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MMP-2, -9 and -14 are reported to be found at the edge of the motile cells, 
on specialized surface protrusions, called invadopodia (Nakahara et al. 1997, 
Bourguignon et al. 1998). The epithelial cell-cell adhesion molecule, E-cadherin, 
can be cleaved by MMP-3 and -7 (Noe et al. 2001). The released fragment of 
E-cadherin promotes tumour cell invasion in a paracrine manner in vitro, by 
binding to and interfering with the function of other full-length E-cadherin 
molecules (Noe et al. 2001). Cleavage of E-cadherin transcriptionally affects the 
epithelial to mesenchymal -transition as well (Birchmeier et al. 1996).
Integrins, a family of heterodimeric cell adhesion molecules composed of 
an α chain and a β chain, are one of the key players in the regulation of cell 
migration. Various α and β chains combinations bind to the specifi c cell surface 
and ECM ligand transmitting signals between the outside and the inside of the 
cells (Giancotti and Ruoslahti 1999, Hynes 2002). MT1-MMP and MT3-MMP 
have been found to be linked to proteolytic cleavage of FAK in vascular smooth 
muscle cells. The FAK receptor can be activated through integrin- mediated 
signals and it can regulate multiple functions such as cell motility, survival and 
proliferation (Shofuda et al. 2004). 
A possible complication in cancer therapy with cell migration inhibiting agents 
is that the migration mechanisms utilized by the cancerous cells and non-neoplastic 
cells are highly similar or identical. Migration of non-neoplastic cells is required 
for example in embryogenesis, infl ammation and wound healing. Hence, targeted 
complete inhibition of these processes eventually leads to undesired detrimental 
side-effects (Friedl and Brocker 2000, Lauffenburger and Horwitz, 1996). 
Cancer dissemination to distant organs through blood or lymphatic vessels, 
penetrating the vascular wall, is a crucial event in metastasis. MMPs can also 
participate in these late events, when the cancer cells must enter, survive and 
exit the blood vessels or lymphatics. MMP-9 is required for intravasation (Kim 
et al. 1998). MMP-14 overexpression increases the number of cancer cells that 
survive intravenous injection in an experimental metastasis assay (Tsunezuka et 
al. 1996). By contrast, MMP activity might not be important for extravasation, 
as TIMP-1 overexpression cancer cell exit the vasculature equally well as control 
cells (Koop et al. 1994). Metastasis growth thus probably also involves MMP 
activity. Furthermore, tissue-specifi c differences may exist among the metastasis- 
promoting proteinase cascades.  
1.5. Matrix metalloproteinase inhibitors
MMPIs could alternatively inhibit or down-regulate MMPs both 
transcriptionally, including signal transduction from cell surface into nucleus, 
and post-transcriptionally comprising modulation of mRNA half-life, secretion, 
localization and activation of proMMPs, and inhibition of active MMPs levels 
(Westermarck and Kähäri 1999). They can be divided in endogenous MMPIs, 
such as TIMPs, inhibitors of MMP synthesis including cytokines, signal 
transduction and transcriptional factors, inhibitors of proMMP activators such 
as anti-MT1-MMP anibodies and inhibitors infl uencing the catalytic site of 
MMPs, a group in which most synthetic MMPIs belong to (Fig. 3).
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Figure. 3. Schematic representation of the possible inhibition levels of MMP 
therapeutic interventions. 
 
1.5.1. Endogenous MMPIs
Two major endogenous inhibitors are known for MMPs, the non-specifi c or 
general inhibitors, such as α2-macroglobulin (α2M), which are present in the 
plasma and tissue fl uids, and the more specifi c inhibitors, called tissue inhibitors 
of metalloproteinases (TIMPs). Four human TIMPs have been identifi ed, which 
are anchored in the ECM or secreted extracellularly. They bind MMPs tightly 
and non-covalently in 1:1 stoichiometric complexes (Brew et al. 2001). They 
differ in tissue-specifi c expression and ability to inhibit various MMPs. The 
potential application of TIMPs to block the MMP activity in cancer was initially 
supported by several studies demonstrating their ability to inhibit tumour growth 
in transgenic mouse models (Kruger et al. 1997, Martin et al. 1999). There 
are numerous examples in which TIMP expression is increased during tumour 
progression, which could be expected to reduce tumourigenic potential. This may 
represent a host-protective stromal response. TIMP-4 can up-regulate the anti-
apoptotic protein Bcl-X, thereby stimulating mammary tumourigenesis (Jiang et 
al. 2001), whereas TIMP-2 shows cell-growth promoting activity (Baker et al. 
2002, Jiang et al. 2002), indicating that their role in vivo is complex, extending 
the MMP inhibition. The expectation that malignant tumours have increased 
MMP expression accompanied by decreased TIMP expression is probably too 
simplistic. However, the possibility of using TIMPs in cancer therapy is limited, 
since protein-based treatments are diffi cult to administer and generally suffer 
from poor pharmacokinetics. Furthermore, TIMPs inhibit a broad spectrum 
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of MMPs and may block the activity of those MMPs that are not necessarily 
overexpressed in a particular tumour or play protective roles against cancer or the 
protective MMPs (Balbin et al. 2003, Owen et al. 2004, Sorsa et al. 2004). There 
are also MMP inhibitors that contain subdomains with structural similarity to 
the TIMPs. These include the procollagen C-terminal proteinase enhancer that 
releases a C-terminal fragment possessing signifi cant MMP inhibitory activity as 
well as the NC1 domains of type IV collagen and tissue-factor pathway-inhibitor-
2, a serine proteinase inhibitor that can also function as an MMP inhibitor (Mott 
et al. 2000, Netzer et al. 1998). RECK (reversion-inducing cysteine-rich protein 
with kazal motifs) is the only known membrane-bound MMP inhibitor and key 
regulator of ECM integrity and angiogenesis (Oh et al. 2001). At present, the 
physiological targets of these putative MMP inhibitory activities remain unclear, 
as does their relevance in cancer.
1.5.2. Inhibitors of MMP synthesis 
There are three main approaches for targeting MMP gene transcription: (i) 
preventing the action of extracellular factors, (ii) blocking signal-transduction 
pathways, and (iii) targeting those nuclear factors that enhance the expression of 
the corresponding MMP gene (Westermarck and Kähäri 1999). The diversity of 
extracellular factors that can mediate MMP production as well as the opposite 
effects of these factors on the expression of different MMP genes, makes it 
diffi cult to select targets. However, recent studies have shown that factors such 
as IFN-α, IFN-β and IFN-γ can be used to inhibit the transcription of several 
MMPs by tumour cells (Kuga et al. 2003, Ma et al. 2001, Slaton et al. 2001). 
Monoclonal antibodies against TNF-α or soluble forms of the TNF receptor are 
effective in treating rheumatoid arthritis. This might possibly be a potential tool 
in cancer treatment as well (Mengshold et al. 2002). Similar strategies to block 
IL-1 or EGF receptors might also be useful for abolishing MMP production 
in cancer (Lal et al. 2002). Retinoids and TGF-β have been reported to down-
regulate the expression of MMPs and increase TIMP expression; however, other 
studies have reported the opposite (Overall et al. 1989, Uria et al. 1998, Overall 
1995, Jimenez et al. 2001).
A second way to target the blocking of MMP production is the signal-
transduction pathways that mediate induction of these enzymes. The blockade 
of specifi c steps in the MAPK pathway can lead to the suppression of MMP gene 
expression in diverse cancer cells. Selective inhibition of p38 MAPK activity 
by SB203580 abolishes the expression of MMP-1, -9 and -13 by transformed 
keratinocytes and SCC cells, and is accompanied by reduced invasion through 
collagen and artifi cial basement membranes (Johansson et al. 2000, Simon et al. 
1998). The specifi c inhibitor (SP600125) of the ERK and JNK pathway has led 
to MMP down-regulation by tumour cells (Shin et al. 2002). Other compounds 
such as halofuginone an alkaloid from the medicinal plant Dichroa febrifuga, 
manumycin A and malolactomycin D can also block MMP gene expression 
through interference with the TGF-β or Ras signalling pathways (Futamura et 
al. 2001, McGaha et al. 2002, Zhang et al. 2002).
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A third way to inhibit MMP production in human tumours is to target 
the nuclear factors directly responsible for MMP transcriptional upregulation. 
Epidemiological studies have suggested that certain dietary factors may act as 
anticarcinogenic agents, and animal models of carcinogenesis have demonstrated 
that perhaps as many as 500 agents may have some effi cacy as chemopreventive 
agents, for example curcumin, natural products of the Indian spice turmeric, 
nobiletin, a fl avonoid that is obtained from Citrus depressa, resveratrol, a 
phytoalexin present in grapes and dykellic acid, a fungal metabolite blocking 
the activity of transcription factors. Glucocorticoids, synthetic terpenoids 
and NSAIDs (non-steroidal anti-infl ammatory drugs) block the activity of 
transcription factors such as AP1 and NF-κB, which regulate the transcription of 
several MMP genes (Hasina et al. 2001, Karin and Chang 2001, Sato et al. 2002, 
Mix et al. 2001, Shishodia et al. 2003, Takada and Aggarwal 2003, Aggarwal 
et al. 2003, Banerji et al. 2004, Woo et al. 2003a, Woo et al. 2003b). However, 
in addition to MMP genes these strategies also  affect the expression of multiple 
genes and they may have several undesired side effects that could be avoided by 
targeting more specifi c factors such as CBFA1, which selectively modulates the 
expression of certain MMPs (Jimenez et al. 2001, Yang et al. 2001a). 
Similarly, restoring the activity of transcription factors such as p53, PTEN 
(phosphatase and tensin homologue) and TEL (translocation-ETS-leukaemia), 
which negatively regulate MMP expression and whose activity is lost in human 
tumours, could downregulate these genes (Ala-aho et al. 2002, Fenrick et 
al. 2000, Koul et al. 2001). It is also possible to target MMP synthesis using 
transfecting cells with antisense mRNA or oligonucleotides, or by targeting 
mRNA with ribozymes, which are RNA molecules that function like enzymes 
and exert a catalytic activity. Ribozymes can be designed to cleave specifi c mRNAs 
and thereby to inhibit protein synthesis (Kondraganti et al. 2000, London et al. 
2003, Ala-aho et al. 2004). Even though there are many opportunities to block 
the production of MMPs, none of them have yet been translated into clinical 
applications. 
1.5.3. Inhibitors of proMMP activation
There are several new possibilities of MMP inhibition based on targeting 
proMMP activation. MT1-MMP is a activator of other proMMPs (-2, -8 and 
-13) and has a pivotal role in regulating tumour growth (Knäuper et al. 1996b, 
Holopainen et al. 2003). Anti-MT1-MMP monoclonal antibodies inhibit 
its proteolytic activity and impair endothelial cell migration and invasion of 
collagen and fi brin gels, and it could thus be a future anti-cancer drug (Galvez 
et al. 2001). Catechins in greentea and red wine polyphenolic compounds block 
the MT1-MMP-dependent activation of proMMPs (Annabi et al. 2002, Oak 
et al. 2004). Furthermore, the complexity of the enzymatic cascade of MMP 
activation provides new possibilities to target tumour MMPs by blocking the 
upstream proMMP-activators such as proMT-MMPs and tumour-associated 
trypsin-2 (Sorsa et al 1997, Paju et al. 2001, Moilanen et al. 2003, Nyberg et al. 
2003, Holopainen et al. 2003). In this regard, a selective furin inhibitor, α1-PDX 
prevents MT1-MMP activation and proMMP-2 processing, with the subsequent 
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attenuation of tumourigenity and invasiveness of human cancer cells (Bassi et al. 
2001). Similar results have been shown using a synthetic furin inhibitor (Maquoi 
et al. 1998). However, it has not shown any inhibitory effect on the activation 
of the secreted convertase-sensitive MMPs. IL-4 and IL-13, anti-infl ammatory 
cytokines, inhibit MMPs via the proMMP activation process (van Lent et al. 
2002). Endostatin is a collagen XVIII-derived 20-kDa proteolytic fragment 
with anti-angiogenic and anti-tumour properties (Kim et al. 2000). It acts as 
an inhibitor of MMP-2 activation (Kim et al. 2000) as well that of MMP-9 and 
MMP-13 (Nyberg et al. 2003). Proteoglycans such as testican-3 and N-Tes can 
suppress proMMP-2 activation mediated by MT1-MMP (Nakada et al. 2001). 
Furthermore human immunodefi ciency virus (HIV) aspartyl protease inhibitor 
blocks proMMP-2 activation, thereby contributing to the regression of these 
highly aggressive tumours (Sgadari et al. 2002). 
1.5.4. Synthetic MMP inhibitors
Most of the synthetic MMP inhibitors target the catalytic site of the MMPs and 
act by chelating the catalytically essential zinc ion. Due to the huge interest in 
the therapeutic intervention of MMPs in cancer, over a hundred small-molecule 
MMP inhibitors have been designed and synthesized (Whittaker et al. 1999). 
The fi rst series of synthetic inhibitors were pseudopeptide derivatives that were 
synthesized to mimic the structure collagen at the site where MMP binds to 
cleave it, called peptidomimetic MMP inhibitors. Hydroxyamate inhibitors bind 
reversibly at the active site of the MMP in a stereospecifi c manner and chelate the 
zinc atom on the enzyme activation site (Betz et al. 1997). Batimastat (BB-94) 
is a low-molecular-weight broad-spectrum hydroxamate-based inhibitor that 
inhibits MMPs and members of the adamalysin family of metalloproteinases 
(Beattie and Smyth 1998). A recent study showed that batimastat promoted liver 
metastasis in a mouse model (Kruger et al 2001), and it showed no signifi cant 
responses in clinical trials. It was replaced by marimastat (BB-2516), a low-
molecular-weight orally bioavailable MMP inhibitor. It is relatively non-specifi c 
inhibiting the activity of MMP-1, -2, -7, -9, -12, -13 and poorly that of MMP-3. 
The drug contains a collagen-mimicking hydroxamate structure that chelates 
the zinc ion at the active site of MMPs (Wojtowicz-Praga et al. 1998). 
Non-peptidic MMPIs have been synthesized on the basis of the three-
dimensional conformation of the MMP zinc-binding site (Hidalgo and 
Eckhardt 2001). They are more specifi c and have better oral bioavailability than 
peptidomimetic inhibitors. BAY 12-9566 is an orally bioavailable synthetic biphenyl 
compound which is a potent inhibitor of MMP-2, -3, -9, and -13 (Rowinsky 2000). 
Prinomastat (AG3340) is a synthetic, low-molecular-weight collagen-mimicking 
MMP inhibitor. It is lipophilic and inhibits the activity of MMP-1, -2, -3, -7, -9 
and -14 as well as tumour growth and angiogenesis in several xenograft models 
(Hidalgo and Eckhardt 2001). BMS-275291 is an orally bioavailable inhibitor of 
MMP-2 and MMP-9, which inhibits tumour growth and angiogenesis. It does not 
inhibit TNF-RII shedding and thus does not cause joint pain as a side effect (Rizvi 
et al. 2004). MMI 270B/CGS27023A is a non-peptidic MMPI and a potent 
inhibitor of MMP-1, MMP-2 and MMP-3 activity (Levitt et al. 2001). MMI-
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166, a selective matrix metalloproteinase inhibitor for MMP-2 and -9, suppressed 
experimental metastasis of human cancers (Katori et al. 2002).
1.5.5. Neovastat
Neovastat is an orally bioavailable extract from shark cartilage. The function of 
neovastat is based on multifunctional antiangiogenic effects. Neovastat can inhibit 
the activity of elastase, MMP-2, MMP-9, MMP-12 and MMP-13. Neovastat 
also inhibits the function of VEGF receptor-2 and induces endothelial cell 
apoptosis (Gingras et al. 2003). The antitumour activity of neovastat has been 
demonstrated in experimental mouse models with human glioblastoma cell graft, 
Lewis lung carcinoma, as well as in melanoma, colon and breast cancer models 
(Gingras et al. 2003). 
1.5.6. Tetracycline derivatives
Tetracyclines, having antimicrobial effects, were already discovered 60 years ago, 
but it was only shown much later that tetracyclines and their derivative doxycycline 
as well as several modifi ed analogues called chemically modifi ed tetracyclines 
(CMT) inhibit MMP activity independently of their antimicrobial action (Golub 
et al. 1992, 1998, Sorsa et al. 1994). Doxycycline and CMT-1 inhibit MMPs 
with different effi ciencies; at therapeutically attainable concentrations doxycycline 
and CMT-1 inhibit MMP-8, -9, -13 and -14 more effi ciently in comparison to 
MMP-1 and -2 (Suomalainen et al. 1992, Greenwald et al. 1999, Lee et al. 
2001, Golub et al. 1995).
Metastat (Col-3, CMT-3) is a synthetic MMPI with limited systemic toxicity 
which belongs to non-antimicrobial CMTs (Lokeshwar et al. 2001). Metastat 
inhibits activated MMPs by interacting with the Ca2+ and Zn2+ binding sites and 
prevents activation caused by oxidation (Sorsa et al. 1998). Metastat inhibits 
the activity of MMP-1, MMP-2, MMP-8, MMP-9, MMP-13 and elastase and it 
downregulates the expression of various infl ammatory cytokines. In preclinical 
studies, metastat inhibited tumour cell proliferation, tumour growth and 
malignant cell invasion into normal lung tissue in rodent models of metastasis and 
it also inhibited tumour-induced angiogenesis and induced apoptosis (Hidalgo 
and Eckhardt 2001, Lokeshwar et al. 2002). In addition to MMPs, metastat 
also affect other proteases, such as human tumour-associated trypsinogen-2 
(Lukkonen et al. 2000). 
1.5.7. Bisphosphonates
Bisphosphonates are synthetic compounds characterized by a P-C-P group. 
They are used to inhibit bone resorption in diseases like osteoporosis and 
Paget’s disease. Bisphosphonates have also recently become important in the 
management of cancer-induced bone disease (Brown et al. 2004). These 
effects mainly consist of inhibition of bone resorption and, when given in large 
amounts, inhibition of ectopic and normal calcifi cation. While the latter effect is 
the consequence of a physical-chemical inhibition of calcium phosphate crystal 
formation, the former is due to a cellular effect involving both apoptosis of 
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the osteoclasts and a destruction of the osteoclastic cytoskeleton, inducing a 
decrease in osteoclast activity. The bond of bisphosphonates is stable in heat and 
most chemical reagents and completely resistant to enzymatic hydrolysis, but 
can be hydrolyzed in solution by ultraviolet light. Bisphosphonates are generally 
well tolerated and have low toxicity. However, patients who had received chronic 
bisphosphonate therapy had necrotic lesions in the jaw; the typical presentation 
is a non-healing tooth-extraction socket or exposed jawbone (Ruggiero et al. 
2004). Many bisphosphonates have been investigated in humans with respect 
to their effects on bone, and eight of them are commercially available today for 
treatment of bone disease (Fleisch, 2002).
1.5.7.1. Pharmacology of bisphosphonates 
The two phosphonate groups of bisphosphonates are linked to the central carbon 
atom by highly hydrolysis-resistant phosphoether bonds. The central carbon 
atom can form two additional covalent bonds, and resulting side chains are 
usually indicated as R1 and R2 (Fig. 4). The P-C-P moiety of bisphosphonates is 
responsible for their strong affi nity for divalent metal ions, such as calcium ions, 
and for the skeleton. Furthermore, when the R1 side chain is a hydroxyl group, 
such compounds are able to chelate calcium ions more effectively, by tridentate 
rather than bidentate binding. An up to 1000-fold increase in potency was 
achieved by the introduction of a primary amino group (-NH2) at the extremity 
of the R2 alkyl chain to form the amino-bisphosphonates (e.g. alendronate, 
pamidronate and neridronate). Amino-bisphosphonates with a secondary amino 
group (e.g. incadronate) and a tertiary amino group (e.g. olpadronate) are even 
more effective, and potency reaches its peak when a tertiary nitrogen is included 
within a ring structure in the R2 side chain (as in risedronate and zoledronic 
acid) (Russell and Rogers 1999). 
Currently, the molecular mechanism(s) through which bisphosphonates 
exert their activity is only beginning to be understood. The bisphosphonates can 
be classifi ed into two major groups with different modes of action. Nitrogen-
containing bisphosphonates inhibit the mevalonate pathway, the main target 
being farnesyl diphosphate synthase (Brown et al. 2004). Inhibition of the 
mevalonate pathway leads to loss of important prenylated proteins which are 
required for post-translation lipid modifi cation (i.e. prenylation) of signaling 
GTPases, such as Ras, Rho and Rac (Rogers et al. 2000). These regulate a 
variety of key osteoclast cell functions, such as control of endosomes, integrin 
signaling, membrane ruffl ing and control of cell morphology, and loss of these 
proteins leads to induction of osteoclast apoptosis. Non-nitrogen-containing 
bisphosphonates have a different mechanism of action. They are metabolically 
incorporated into non-hydrolysable analogues of ATP, ultimately also leading to 
osteoclast apoptosis. As a consequence of this osteolysis is effectively inhibited. 
These metabolic reactions are likely to be catalysed by members of the family of 
type 2 class of aminoacyl-tRNA synthetases, which play a pivotal role in protein 
synthesis (Rogers et al. 1996).
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Figure 4. Bisphosphonate chemical structure. The two phosphonate groups 
are linked to the central carbon atom by phosphoether bonds. The carbon atom 
forms two additional covalent bonds, and the resulting side chains are referred 
to as R1 and R2.
 
1.5.7.2. Anti-tumour effects of bisphosphonates 
Increasing evidence is accumulating in vitro and in vivo that bisphosphonates are 
able to directly affect tumour cells by mechanisms such as apoptosis induction, 
inhibition of cell growth, inhibition of invasive behaviour and inhibition of 
angiogenic factors, in addition to their direct effects upon osteoclasts. The 
potency of the anti-tumour effect in vitro generally mirrors the potency of the 
anti-resorptive ability with nitrogen-bisphosphonates, in particular, zoledronic 
acid being the most potent in both respects. 
Bisphosphonates can induce apoptosis of tumour cells and inhibit tumour 
cell growth of a variety of tumour cell types in vitro (Fromigue et al. 2000, 
Senaratne et al. 2000, Jagdev et al. 2001a, Lee et al. 2001, Riebeling et al. 2002, 
Mackie et al. 2001, Sonnemann et al. 2001, Cheng et al. 2004, Shipman et al. 
1998). These results are consistent with earlier reports that bisphosphonates can 
inhibit cell proliferation and induce apoptosis in osteoclast (Ito et al. 1999) and 
in J774 macrophage-like cells (Selander et al. 1996). Nitrogen-bisphosphonates 
pretreatment of prostate and breast carcinoma cell lines has been shown to inhibit 
tumour cell adhesion and spreading in parallel to their antiresorptive potency  to 
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unmineralized and mineralized bone extracellular matrices in a dose-dependent 
manner, whereas non-nitrogen-bisphosphonates have little or no effect (van 
der Pluijm et al. 1996, Boissier et al. 1997). Furthermore bisphosphonate 
recognition by tumour cells did not modulate cell surface integrin expression 
(Boissier et al. 1997). The growth inhibition of breast cancer cells induced by 
both bisphosphonate groups is augmented by p38 MAPK pathway inhibition in 
vitro (Merrell et al. 2003).
MMPs, important for normal and malignant remodelling, evidently contribute 
to bone metastases. Bone marrow stromal cells from myeloma patients secrete 
MMP-1 and MMP-2. MMP-1 initiates bone resorption by degrading type I 
collagen, which becomes a substrate for and can also be directly degraded by 
MMP-2 (Barille et al. 1997, Konttinen et al. 1998). Malignant plasma cells have 
been found to upregulate MMP-1, MMP-8 and MMP-13 and to activate MMP-2 
(Derenne et al. 1999, Wahlgren et al. 2001). The bisphosphonates exert varying 
inhibitory effects on MMPs, including inhibition of their enzymatic activity; the 
ability of bisphosphonates to act as direct inhibitors of the activity of MMPs was 
originally discovered by our group (Teronen et al. 1997a, 1997b, 1998, 1999, 
2001). Many studies have thereafter provided evidence for a direct cellular effect 
of bisphosphonates in preventing tumour cell invasion and an inhibitory effect 
of bisphosphonates on the proteolytic activity of MMPs (Montague et al. 2004). 
In osteoblasts, alendronate at concentrations higher than 10 µM markedly 
stimulated the synthesis of MMP-13 mRNA and immunoreactive protein, but did 
not stimulate the transcriptional rate of the MMP-13 gene. Alendronate did not 
alter the expression of TIMP-1 and -2, but modestly stimulated the expression of 
TIMP-3. The actions of alendronate in osteoblasts suggest potential additional 
effects in bone remodelling (Varghese and Canalis, 2000).
When tumour cells were injected into the bone medullary cavity of SCID 
mice femurs both in vivo and following isolation in vitro, the levels of MMP-
2 and MMP-9 secreted in the bone medullary cavity of the femurs directly 
correlated with the extent of collagen I release, while alendronate pretreatment 
in vivo blocked both MMP production by the tumour cells and the release of 
osteoclasts and collagen I (Stearns and Wang 1998). Clodronate can directly 
inhibit the activities of MMP-1 and MMP-8 in vitro (Teronen et al. 1997a, b). 
Alendronate inhibited the secretion of MMP-2, and it prevented the inhibitory 
effect of TIMP-2 on MMP-2 degradation by plasmin and thereby enhances 
inactivation of MMP-2 (Farina et al. 1998, Stearns et al. 1998, Cheng et al. 
2004). Zoledronate inhibited both IL-6 and MMP-1 production in bone 
marrow stromal cells, but up-regulated MMP-2 secretion from bone marrow 
stromal cells (Derenne et al. 1999). 
Bisphosphonates have anti-angiogenic effects as well. Osteoblastic cells in 
bone marrow produce both VEGF and b-FGF, and vascularization is needed for 
osteoclastic bone resorption. Intravenous zoledronic acid or pamidronate, given 
as treatment for metastatic bone disease to breast cancer patients, decreased 
bone marrow plasma values of b-FGF and VEGF (Jagdev et al 2001b), while 
pamidronate decreased serum VEGF of cancer patients with a variety of solid 
tumours (including non-small cell lung cancer, breast, prostate and bladder 
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cancers) that had metastasized to bone (Santini et al. 2002). Zoledronic acid and 
pamidronate have also been shown to decrease b-FGF- and, to a lesser extent, 
VEGF-induced proliferation of vascular tissue in a murine soft tissue model of 
angiogenesis (Wood et al. 2002). 
In vitro, bisphosphonates can enhance the anti-tumour activity of known 
cytotoxic agents that are commonly used in the clinical setting, but very little 
is known about how bisphosphonates interact with commonly used cytotoxic 
agents (Magnetto et al. 1999). Zoledronic acid has shown synergy with paclitaxel 
in vitro in breast cancer treatment (Jagdev et al. 2001a) and with dexamethasone 
in myeloma (Tassone et al. 2000). Other bisphosphonates in combination 
with cytotoxic drugs have at best shown additive activity, e.g. ibandronate in 
combination with taxanes in breast cancer (Magnetto et al. 1999), or no effect, 
e.g. pamidronate in combination with the chemotherapy agent dacarbazine 
(Riebeling et al. 2002). The new bisphosphonate minodronate (YM529) with 
the chemotherapy agent etoposide further inhibited the production of bone 
metastasis and signifi cantly prolonged survival of human small-cell lung cancer-
bearing mice (Yano et al. 2003). Furthermore, the nitrogen-bisphosphonates 
activated the human γδT cell population, which shows potential cytotoxic activity 
toward a broad spectrum of tumours (Kunzmann et al. 1999, 2000).
Bisphosphonates reduce tumour osteolysis and bone destruction and prolong 
survival in animal tumour models. The 4T1 orthotopic murine mammary 
tumour cell model, where cells are injected into the mammary fat pad, mimics 
the human situation. Zoledronic acid not only led to a reduction in new bone 
metastases and osteolysis, but interestingly also inhibited progression of excisting 
lesions. Non-osseous tumour was however not affected (Mundy et al. 2001). 
Mice receiving both ibandronate and TIMP-2 transfected breast cancer cells 
exhibited no radiologically detectable osteolytic lesions (Yoneda et al. 1997). 
Other bisphosphonates in similar animal models have either shown no effect 
(Krempien and Manegold 1993) or an adverse effect (Kostenuik et al. 1993). In 
a model of breast cancer bone metastases, risedronate inhibited the development 
of bone metastases, and for those mice receiving continuous risedronate, survival 
was increased compared with untreated mice. However, while risedronate-treated 
animals had a signifi cant decrease in bone tumour load, there was a greater amount 
of metastatic invasion into soft tissues surrounding bone when compared with 
the untreated animals. In contrast, the experimental bisphosphonate YH529, 
when started the same day as MDA-MB-231 breast cancer cell inoculation into 
nude mice reduced non-osseous metastases, in addition to the inhibition of bone 
lesions and tumour burden in bone (Sasaki et al. 1998). 
1.5.7.3. Bisphosphonates in anti-cancer therapy
Bone is a preferred site of metastasis for many solid tumours, and the 
complications associated with bone metastases can result in signifi cant skeletal 
complications, including pathologic fractures, bone pain, impaired mobility, 
spinal cord compression and hypercalcaemia. Bisphosphonates are the current 
standard of care for preventing skeletal complications associated with bone 
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metastases inducing a diminution of bone resorption, leading to a decrease 
in hypercalcaemia, new osteolytic lesions and fractures, and leading to an 
amelioration of pain and an improvement of the quality of life (Fleisch 2002). 
In addition, bisphosphonates may prevent cancer-treatment-induced bone loss 
(CTIBL) and the development of malignant bone disease in patients with early-
stage cancer (Lipton 2004). Additionally, there is increasing evidence to support 
the adjuvant use of bisphosphonates in breast cancer, and confi rmatory studies 
are in progress (Lipton 2004). 
Bone metastases are common in patients with many types of cancer, especially 
breast and prostate cancer. Patients with multiple myeloma, lung cancer, bladder 
cancer, renal cell carcinoma, thyroid cancer and melanoma are also at high risk for 
skeletal complications (Coleman 2004). Patients who receive adjuvant hormonal 
therapy for breast cancer or androgen-deprivation therapy for prostate cancer are 
at an especially high risk for CTIBL because of reduced oestrogen signalling. 
Oral clodronate, oral risedronate, and i.v. zoledronic acid have all demonstrated 
promise in preventing CTIBL in patients receiving hormonal therapy for breast 
cancer. In breast cancer and myeloma, bisphosphonates have now become 
part of standard therapy to treat and prevent skeletal-related events and, until 
recently, treatment was largely with intravenous pamidronate or oral clodronate. 
Zoledronic acid is the only bisphosphonate that has been compared directly with 
pamidronate, and it was shown by multiple event analysis to be signifi cantly 
more effective at reducing the risk of a skeletal-related event (Coleman 2004). 
In patients with prostate cancer, clodronate, etidronate and pamidronate have 
demonstrated transient palliation of bone pain. 
More recently, several large, long-term clinical trials have provided confl icting 
evidence of the clinical anti-tumour effects of oral clodronate. Diel et al. (1998) 
described a reduction in bone and visceral metastases, and an improvement in 
survival in patients with bone marrow-disseminated tumour cells. On the other 
hand, Saarto et al. (2001) reported increased incidence of bone and visceral 
metastases and a poorer survival in node-positive breast cancer patients after a 
median follow-up of 5 years. 
However, zoledronic acid is the only bisphosphonate to demonstrate 
both signifi cant and sustained pain reduction and a signifi cantly lower 
incidence and longer time to onset of skeletal-related events compared with 
placebo (Lipton 2004). Zoledronic acid also has signifi cant clinical benefi t 
in patients with bone metastases from a variety of other solid tumours, 
including lung cancer and renal cell carcinoma (Coleman 2004, Lipton 2004). 
1.6. Clinical use of MMPIs for cancer treatment 
The fi rst synthetic MMPIs were developed in the early 1980s. MMPs have been 
heralded as promising targets for cancer therapy on the basis of their massive up-
regulation and activation together with tissue-destructive action on ECM and 
BM components in malignant tissues. Preclinical studies testing the effi cacy of 
MMP suppression in tumour models were so compelling that synthetic MMPIs 
were rapidly developed and routed into human clinical trials. Nevertheless, the 
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results of these trials have been disappointing. First-generation MMPIs were 
hampered by poor bioavailability and were rapidly replaced by second-generation 
orally active drugs (Whittaker M et al. 1999). Marimastat was in phase III for the 
treatment of cancer, but it has been discontinued due to the lack of effi cacy and 
musculoskeletal side-effects. All clinical trials with BAY-12-9566, CGS-27023A 
(MM-270, MMI-270) and prinomastat  have been stopped as well (Peterson 
2004).   
Continued investment in MMPI development has been sustained despite a 
growing litany of failed clinical trials. At present the clinical use of neovastat 
and metastat is ongoing, and some novel MMPIs are in clinical development 
in cancer therapy (Peterson 2004). Metastat seems to be well tolerated, with 
photosensitivity and fatigue being the most frequently encountered side effects 
and it is being examined in the treatment of Kaposi’s sarcoma (Peterson 2004). 
In phase I trials, metastat was found to induce disease stabilization in several 
patients who had a non-epithelial type of malignancy; metastat was also able to 
lower plasma MMP-2 levels, and it can suppress the production of both MMP-2 
and MMP-9 when measured in plasma or skin biopsies in cancer patients (Rudek 
et al. 2001, Vihinen and Kähäri 2002). In these studies, phototoxicity was found 
to be dose-limiting, and in some patients treatment with metastat has been 
associated with reversible sideroblastic anaemia (Rudek et al. 2001). Metastat is 
currently in a phase I/II study in patients with progressive or recurrent high-
grade anaplastic astrocytoma, anaplastic oligodendroglioma or glioblastoma 
multiforme (Vihinen and Kähäri 2002).
Neovastat is in phase III trials for the treatment of advanced non-small-cell 
lung cancer, metastatic renal-cell carcinoma and multiple myeloma (Falardeau et 
al. 2001). Furthermore, S-3304, rebimastat, CP-471358 and BMS-275291 are 
currently being investigated in phase I/II studies to evaluate the effi cacy of these 
inhibitors. The broad-spectrum BMS-275291 has not shown musculoskeletal 
side-effects (Lockhart et al. 2003, Peterson 2004).
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Proteolytic degradation of the ECM and BMs is essential in tumour progression. 
It allows cells to migrate beyond physical barriers, get to the blood stream and 
metastasize. Clinical trials with MMPIs have been disappointing because it is very 
likely that too excessive broad-spectrum blocking of MMPs lead to exclusion of the 
defensive or protective action of MMPs (Balbin et al. 2003, Owen et al. 2004).
Bisphosphonates are well-tolerated and frequently used drugs in bone 
diseases. The molecular mechanism of bisphosphonates, especially their effects on 
malignant cell migration and direct effects on MMPs, is not fully understood.
Furthermore, it is evident that gelatinases (MMP-2 and MMP-9) play a central 
and pivotal role in angiogenesis and affect the prognosis of cancer patients. When 
this research was initiated, no specifi c or selective gelatinase inhibitors or gelatinase-
targeting compounds existed. The specifi c aims of this thesis were to study:
1.  The effects of bisphosphonate (alendronate) on human fi brosarcoma, 
melanoma and endothelial cell invasion and random migration.
2.  The direct effects of alendronate, clodronate, pamidronate and zoledronate 
on the catalytic activities of MMP-1, -2, -3, -9, -12, -13 and -20 and 
urokinase type plasminogen activator.
3.  The effects of clodronate on the activation of proMMP-2, the expression of 
MT1-MMP mRNA and protein production by human MG-63 osteosarcoma 
cell line as well as on catalytic activity of pure human recombinant MT1-
MMP.
4.  To develop novel MMP-2 and MMP-9 inhibitors to target selectively 
human gelatinases expressing tumours.
5.  To study the usefulness of these small, cyclic CTT1 and CTT2 peptides 
as anti-cancer agents in vitro and in vivo using human tongue carcinoma 
cells.
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3. Materials and Methods
A summary of the methods used is described. Detailed methods are described in 
the original publications I-IV.
3.1. Cell lines and cell cultures (I, II, III, IV).
Human HT1080 fi brosarcoma, human C8161 melanoma, human umbilical vein 
endothelial (HUVEC) and its derivative Eahy926, human tongue squamous cell 
carcinoma HSC-3, human SKOV-3 ovarian carcinoma, KS6717 Kaposi’s sarcoma-
derived, human MDA-MB-435 breast carcinoma and human osteosarcoma 
MG-63 cell lines were maintained in DMEM or RPMI supplemented with 10% 
FCS, L-glutamine, penicillin-streptomycin andhypoxanthine/aminopterin/
thymidine additive with the Eahy926 cells and HEPES and endothelial cell 
growth supplement with HUVEC cells.
3.2. In vitro cell migration and invasion assays (I, III, IV).
Cell migration was studied using 8.0-mm-pore size and 6.5-mm-diameter 
Transwell inserts (Costar). Tumour cell invasion was studied using 6.4 mm-
diameter Boyden chambers precoated with Matrigel (BD Biosciences). The layer 
of Matrigel matrix serves as reconstituted BM in vitro. The cells with or without 
various concentrations of bisphosphonates or peptides were allowed to migrate in 
the presence of 10% FCS containing culture medium. The cells that migrated to 
the underside of the membrane were stained with toluidin blue and quantitated 
by scanning with Bio-Rad scanner or counted under light microscope. 
3.3. Cell viability, adhesion and proliferation assays 
(I, III, IV).
To assess the effect of different concentrations of bisphosphonates and peptides on 
cell viability, cells were plated in microtiter wells and after culturing for 20 hours, 
viability was determined with the MTT reagent according to the instructions of 
the manufacturer (Sigma). For cell adhesion studies microtiter wells were coated 
with fi bronectin and blocked with BSA. Cells were added together with various 
concentrations of bisphosphonates or peptides and cultured for 1 h in a serum-
free medium. After washing twice with PBS the bound cells were determined 
with the MTT reagent as above. To assess the effects of CTT1 and CTT2 
peptides on cell proliferation, cells were plated in microtiter wells culturing for 
24 h. The proliferation was determined with the Cell Proliferation ELISA, BrdU 
kit (Roche), where BrdU incorporation to newly synthesized DNA is measured 
in proliferating cells.
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3.4. Measurement of mRNA expression (II, IV).
The total cellular protein and RNA were isolated by the Trizol® kit (Gibco) or 
Rneasy Mini Kit and QIAshredder (Qiagen) after culturing cells with various 
concentration of peptides in serum-free media. Ribonuclease protection assay 
(RPA) was carried out using RPA III™ Ribonuclease Protection Assay Kit 
(Ambion Inc.). Labelled MMP-9 RNA probe was hybridized with total RNA 
according to the manufacturer’s instructions. The protected RNA fragment was 
run on 5% denaturing polyacrylamide gel and visualized on an X-ray fi lm. A 28S 
probe was used as internal control.
For Northern blot analysis equal amounts of the RNA samples were 
fractionated on 0.7% agarose, 18% formaldehyde gels. The gels were stained with 
ethidium bromide for visualization of the rRNAs, and the RNA was transferred 
onto a fi lter after being photographed. Hybridization was carried out with 32P-
labelled MMP-2 (2733 bp fragment) or MT-MMP1 (420-bp fragment) cDNA 
clones as recommended for Zeta-Probe (Sigma). The fi lters were washed and 
exposed to Kodak X-Omat fi lm for 18 to 48 h with an intensifying screen at 
-70°C. The autoradiographs and photographs were analysed by quantitative 
densitometry using PhosphorImage. 
3.5. Phage display and peptide synthesis (III).
Phage display peptide libraries CX5C, CX6C, CX7C, CX9 were prepared as 
described earlier (Koivunen et al. 1995). For selection of MMP-9-binding 
phage APMA-activated human neutrophil MMP-9 (100 µg/ml) was coated on 
microtiter wells at 4°C. The wells were then saturated with 5% BSA. In the fi rst 
panning, the wells were incubated overnight at 4°C in 5 mM TBS buffer (Tris-
HCL/0.1 M NaCl, pH 7.5) containing 1% BSA. After extensive washing, the 
bound phages were eluted with a low pH buffer. In subsequent pannings, the 
amplifi ed phages were allowed to bind for 1 h at 22°C. Randomly selected clones 
were amplifi ed over night and sequenced using Sequenase 2.0 kit (Amersham).
3.6. In situ zymography (IV).
Untreated frozen tissue sections were thawed and warmed to room temperature. 
Sections were covered with in situ zymography (ISZ)-buffer (50 mM Tris-HCl, pH 
7.4; 1 mM CaCl2) alone, with 100 µM CTT2, CTT1 and C1 peptides, all dilutions 
in ISZ-buffer or 10 mM 1,10-phenanthroline. After 30 min incubation the solution 
was discarded and samples were covered with ISZ-mix consisting of DQ™ Gelatin 
(Molecular Probes) mixed 1:2 with 1% low melting point-agarose (Sigma) and 2-
(4-amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI) at 1 µg/ml was 
included to stain nuclei. The same inhibitors as used in the pre-incubation were 
added at indicated concentrations to the substrate solution. Samples were covered 
with equal amounts of ISZ-Mix with or without inhibitors and allowed to gel at 
room temperature for 30 min. Thereafter, samples were incubated at +37ºC for 
12-48 h. Green fl uorescence was regarded as gelatinolytic activity in the otherwise 
uniformly dark quenched gelatin layer (Pirilä et al. 2001).
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3.7. Mouse experiments (III, IV). 
The animal experiments were approved by the Committee for Animal Experiments 
of Helsinki University (IV) and the Animal Care and Use Committee of the 
Burnham Institute (La Jolla, CA) (III). Human tumour xenografts were 
established in mice by administering 106-107 tumour cells per mouse in a 200-µl 
volume of serum-free DMEM. KS1767 and MDA-MB-435 cells were injected 
into the fat mammary pad of athymic mice, SKOV-3 cells into the peritoneal cavity 
of SCID/SCID mice (n=5)  and HSC-3 cells subcutaneously into the right and 
left back of athymic mice (n=7 male and 9 female)  (Harlan-Sprague-Dawley). To 
study the effect of CTT1 on tumour implantation, CTT1 was premixed with the 
tumour cells ex vivo, prior to the cell implantation. Alternatively, CTT1, CTT2 
or control peptides were administered to established tumours either as a systemic 
(i.p. or i.v.) or as a local (s.c.) treatment. Tumour volumes were calculated and 
mouse survival was followed. 
3.8. Colorimetric assay for MMPs using modifi ed pro-
urokinase as substrate (I, II).
The autoactivated and APMA (1 mM)-pretreated human MMPs were incubated 
with bisphosphonates at concentrations indicated in the text, and assayed for 
MMP activities according to Verheijen et al. (1997). The high and low Ca2+ 
concentrations were 5 and 1 mM CaCl2, respectively, in 50 mM Tris-HCl, 150 
mM NaCl, 1 µM ZnCl2, 0.01% Brij, pH 7.8 (TNC buffer). The activities were 
expressed as relative units. uPA activity was assayed with chromogenic S2444 
substrate (Chromogenix).
3.9. Measurement of type I collagenase activity (IV).
Collagenase activity was determined by incubating human recombinant 
collagenase-1 or MMP-1 (Calbiochem), collagenase-2 or MMP-8 (Chemicon 
International) and collagenase-3 or MMP-13 (Invitek) with 1.5 µM soluble 
native human skin type I collagen for 12 h at 22ºC. MMP-1, -8 and -13 were 
pretreated with 100 µg/ml CTT2 in buffer at 37ºC for 60 min with 1 mM 
APMA. The characteristic ¾- and ¼-cleavage products of type I collagen 
resulting from collagenase action were separated and analysed by 8% SDS-PAGE 
and quantitated by densitometry (Hanemaaijer et al. 1997). 
3.10. Western blot analysis (II).
Western blot analysis for MMP-2 and MMP-13 was performed from cell culture 
media and for MT1-MMP from MG-63 osteosarcoma cell lysates. The samples 
were adjusted to contain equal amounts of protein for each experiment and samples 
were separated on 8 or 10% SDS-PAGE gels and electrophoretically transferred 
to a nitrocellulose membrane. Nonspecifi c binding was eliminated using PBS 
supplemented with 5% non-fat dry milk for 90 min at 37°C. The membrane 
was incubated with monoclonal antibodies against MMP-2, MMP-13, or with 
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polyclonal antibody against MT1-MMP (Calbiochem; dilution 1:500 for each 
antibody) for 10 h. The membranes were incubated with alkaline phosphatase-
conjugated rabbit anti-mouse IgG antibody for monoclonal antibodies and 
goat anti-rabbit IgG antibody for polyclonal antibody for 1 h. Thereafter the 
immunoblots were developed by addition of nitro blue tetrazolium (NTB), and 
5-bromo-chloro-3-indolyl-phosphate (BCIP) diluted to N-N-dimethylformide 
in 100 mM Tris-HCL, 5 mM MgCl2, 100 mM CaCl2; pH 9.5. All incubations 
were performed at 22°C.
3.11. Gelatin zymography (I, II, III, IV).
The enzymatic activity and molecular weight of electrophoretically separated forms 
of gelatinolytic enzyme were determined from the cell culture media of tumour 
cells using gelatin zymography. Samples were incubated with Laemmli s´ sample 
buffer after which the samples were separated in polyacrylamide (8 or 10% SDS) 
gel containing 1 mg/ml gelatin. The enzymes were renatured by series of buffers 
and incubated overnight at 37°C in buffer containing Ca2+ and Zn2+. The reaction 
was stopped with Coomassie Brilliant Blue R250 staining, followed by destaining. 
The zymograms were quantifi ed by densitometer scanning of the photos.
3.12. Enzyme inhibition assays (I, II, III, IV).
To determine the inhibitory effects of the synthetic peptides and bisphosphonates, 
purifi ed MMPs were preincubated for 60 min with peptides and bisphosphonates 
at concentrations indicated in the text. The substrates, a 21-kDa β-casein (52 mM) 
or [125I]-gelatin, and samples described above or cell culture media were incubated 
for 1 or 2 h at 37°C. Degradation of 21 kDa β-casein was analysed by SDS gel 
electroforesis. The degradation of [125I]-gelatin was determined by counting 
radioactivity in the supernatant after precipitation of undegraded gelatin with 
20% trichloroacetic acid. The radioactivity in the supernatant refl ected gelatinase 
activity.
3.13. Immunohistochemistry (IV).
For the identifi cation the carcinoma and endothelial cells, the frozen tissue 
sections were stained with CK-PAN and FVIII, respectively. Vectastain rabbit/
mouse ABC Elite kits (Vector Labs) were used according to the protocol. The 
tumour tissue sections were fi xed in acetone, incubated with 0.6% H2O2 in 
methanol for 30 min, and blocked with normal goat/horse serum (1:50) for 20 
min. Sections were incubated overnight at +4°C with polyclonal FVIII antibody 
(dilution 1:5000, DAKO) and monoclonal CK-PAN antibody (1:700, DAKO). 
The protein-antibody complex was detected by incubating with biotinylated anti-
rabbit/-mouse immunoglobulin G for 30 min and with avidin-biotin complex 
for 30 min. The slides were stained with 3-amino-9-ethylcarbazole (AEC) and 
counterstained with Mayer’s haematoxylin. The microvessels were counted in 
four chosen x 400 fi elds in the highest vessel density areas. Serial sections of the 
slides were also stained with the van Gieson staining method.
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3.14. Immunomagnetic isolation analysis and identifi cation 
for HSC-3 cells in PBMC suspension (unpublished). 
Peripheral blood mononuclear cells (PBMCs) were separated from buffy coat 
preparation of human blood by the modifi ed dextran-Ficoll method. Dilution 
series of HSC-3 cells were prepared to determine the sensitivity of the detection 
system. The samples were resuspended HSC-3 cells at concentrations of 0, 10, 
100 and 1000 cells in 2 x 107 PBMNCs in 1 ml of PBS/20% FCS. CELLectionTM 
Epithelial Enrich Kit (Dynal, Oslo, Norway) contains superparamagnetic 
Dynabeads (4.5 µm diameter) coated to an antibody via a DNA linker. The 
antibody coated onto the CELLection™Dynabeads is an anti-EpCAM (epithelial 
cell adhesion molecule) mouse IgG1 monoclonal (Ber-EP4) specifi c for two (34 
and 39 kDa) glycopolypeptide membrane antigens.  Dynabeads with anti-mouse 
antibody only were used as a negative control. The different concentrations of 
HSC-3 cells with 2x107 PBMNCs were incubated with 2x107 immunobeads for 
30 min at 4°C. Following incubation the cell suspension was placed against the 
magnet (Dynal MPC®) for 2 min to recover the carcinoma cells surrounded 
by the beads as rosettes. The supernatant containing the unbound cells was 
discarded. The test tubes were washed four times in 1000 µl RPMI/1% FCS. 
Cells were released using 200 units Dnase by incubating for 15 min at room 
temperature. The test tube was placed against the magnet for 3 min, and the 
supernatant containing the released cells was removed and transferred to a new 
test tube. 200 ml RPMI /1% FCS was added to resuspend the beads attached to 
the tube wall and after the magnet treatment, the supernatant was transferred 
to the same new test tubes. Cytotech slides were prepared from the released 
cells, air-dried overnight and stored at -80°C prior to immunocytochemical 
stainings. 
The cytotech slides were stained with an EPIMET* epithelial cell detection 
kit (Baxter, Munich, Germany) according to the manufacturer’s instructions 
(unpublished data). Briefl y, cells were permeabilized, fi xed and incubated with 
the conjugate of the murine monoclonal antibody A45-B/B3. The Fab fragments 
were conjugated to alkaline phosphatase (AP). Subsequently, an insoluble red 
reaction product (New Fuchsin) was developed at the binding site of the Fab-AP 
conjugate. The cells were counterstained with Mayer’s haematoxylin to evaluate 
nuclear morphology. The slides were evaluated by light microscopy. Negative 
control staining experiments were performed with irrelevant (anti-FITC) isotopic 
antibodies. 
To evaluate the expression of MMP-9 immunoreactive protein by HSC-3 
cells the stainings were performed with polyclonal MMP-9 antibody (1:1000, 
Neomarkers, Fremont, CA, USA), using the VECTASTAIN®‚ Elite ABC Kit 
(Abbott, Chicago, IL, USA) as described above. Negative controls were stained 
with phosphate-buffered saline (PBS) and normal rabbit IgG instead of the 
primary antibody.
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3.15. Immunofl uorescence (II).
MT1-MMP expression in MG-63 cell monolayers was detected by using an 
indirect immunohistochemical staining (II). After the cells were grown at 
indicated concentrations of clodronate with serum-free medium, the cell layers 
were incubated with primary monoclonal MT1-MMP antibody (Oncogene 
Research Products™, Darmstadt, Germany), diluted at 1:80 in 1% BSA in PBS 
with 150 mM NaCl and incubated overnight in a humid chamber at 4°C. After 
washing the samples were incubated with fl uorescein-conjugated rabbit anti-
mouse immunoglobulins (1:60) (DAKO, Glostrup, Denmark) for 30 min at 
room temperature. The slides were examined by fl uorescent microscopy.
3.16. Statistical analysis (I, II, III, IV).
Data are expressed as means ± standard deviation and the signifi cance of differences 
between group means was determined by Student’s t test. Data were considered 
as signifi cant when at least p=0.05 was reached. Statistical differences in the 
Kaplan-Meier survival were determined by Log-Rank and Wilcoxon tests.
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4.1. Inhibition of human MMPs and uPA by 
bisphosphonates (I, II).
Pamidronate and zoledronate inhibited dose-dependently human macrophage 
metalloelastase (MMP-12) and enamelysin (MMP-20). Alendronate, pamidronate 
and zoledronate at a concentration range of 20-1000 µM inhibited the 
degradation of the 21-kDa β-casein band by human recombinant MMP-8, -3 and 
-13 in a dose-dependent manner. Alendronate and clodronate dose-dependently 
inhibited the activities of purifi ed human MMP-1, -2, -3, -8, -9 and -13, but 
did not inhibit the serine proteinase uPA. The ability of 400 µM alendronate 
and clodronate to inhibit MMP-1, -2, -3, -8, -9 and -13 was reduced in the 
presence of high (5 mM) Ca2+ concentration in the assay buffer. In the presence 
of low or physiological (1 mM) Ca2+ concentration in the assay buffer the IC50 
for MMP inhibition was 40-70 µM. Corresponding results were observed using 
ß-casein and radioactive gelatin-degradation assays. When 50 µM alendronate, 
pamidronate or zoledronate were added together with substrate to enzyme 
reactions, a clear inhibition was observed after 20-40 min.
4.2. The effects of alendronate on cell invasion, migration, 
viability and adhesion (I).
Alendronate at 50, 100 and 500 µM concentrations inhibited signifi cantly, 
effi ciently and dose-dependently the random migration and the invasion of 
HT1080 fi brosarcoma cells and C8161 melanoma cells through type IV collagen-
coated Matrigel cell culture inserts (Table 2). Futhermore, alendronate reduced 
dose-dependently and signifi cantly the migration of human endothelial cell lines 
(Eahy926 and HUVEC). As a positive control for the cell invasion and random 
migration assays we used CTT1 (500 µM), which signifi cantly reduced the 
Matrigel invasion and random migration of the HT1080 fi brosarcoma, C8161 
melanoma and endothelial cell lines (Table 2). Alendronate did not decrease the 
growth of C8161 melanoma cells at any of the concentrations studied. At the 
500 µM concentration, alendronate partially decreased the growth of HT1080 
fi brosarcoma cells during a 24-h culture, but did not affect the cells at the 50 or 
100 µM concentrations, which are the concentrations that signifi cantly inhibited 
cell invasion and random migration. Furthermore, alendronate signifi cantly 
promoted the adherence of both HT1080 fi brosarcoma and C8161 melanoma 
cell lines to fi bronectin and Matrigel substrata when compared to untreated cell 
lines. The CTT1 peptide did not affect cell adhesion for fi bronectin, was not 
toxic to cells and did not affect cell viability.
4. RESULTS
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Table 2. Effect of alendronate on cell migration and invasion. The respective 
levels of dose-dependent inhibition (%) of HT1080 cell and C8161 cell migration 
and invasion compared to buffer alone.  
ND= not determined, n = 3, p ≤ 0.05
Migration Invasion
Cell lines Alendronate
50       100      500µM
Alendronate
50       100       500µM
HT 1080
C 8161
HUVEC
Eahy926
29%       53%     87%
31%       41%     65%
23%      34%     95%
58%      69%     92%
72%     84%       98% 
62%     77%       86%
ND     ND        ND
ND     ND        ND
4.3. Proteolytic activation of MMP-2 by PMA and the 
effects of clodronate on MMP-2 activation in human 
osteosarcoma cells (II).
Densitometric analysis of 72 kDa proMMP-2 activation induced by PMA showed 
that 10-7 M PMA treatment for 24 h resulted in the production and conversion 
of Mr 72 kDa latent proMMP-2 to Mr 62 kDa active MMP-2 species in the 
conditioned medium of human MG-63 osteosarcoma cells, thus evidencing 
clear MMP-2 activation. Human MG-63 osteosarcoma cells were then exposed 
to different concentrations of clodronate and the resulting culture supernatants 
were evaluated accordingly by gelatin zymography. In PMA-induced MG-63 
cell culture media the percentage of the activated form of MMP-2 in respect to 
total MMP-2 amount was 11.8 (SD±0.25), and 0.1 mM clodronate decreased 
this percentage to 10.9 (SD±0.78, 1.74, p=0.5; n = 6). A signifi cant decrease to 
4.3% (SD±0.78, p<0.01) and to 0% (SD±0, p<0.01) was observed with 1.0 mM 
and 2.5 mM clodronate concentrations, respectively.
4.4. MMP-2 and MT1-MMP mRNA expression (II).
Total RNA was extracted from MG-63 cells, and the steady-state levels of MT1-
MMP and MMP-2 transcripts were compared by Northern analysis. Relative 
hybridization signal numbers were calculated by ascribing an arbitrary value of 
1 to the signal seen on the Northern blot of MG-63 cells without clodronate 
treatment after dividing the scanning units of mRNA levels per corresponding 
ribosomal RNA units determined using a PhosphorImager. The relative MT1-
MMP mRNA expression levels were 1, 0.52, 0.36, and 0.25 for 0 mM, 0.1 mM, 
1.0 mM and 2.5 mM of clodronate, respectively, and the relative levels of MMP-
2 mRNA expression were 1, 0.76, 0.68, and 0.50 for 0 mM, 0.1 mM, 1.0 mM, 
and 2.5 mM of clodronate, respectively.
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4.5. Production of MMP-2, MMP-13, and MT1-MMP in 
human osteosarcoma cells and gelatinolytic activity of 
MT1-MMP in conditioned human cell culture medium (II).
In the Western immunoblot analysis the protein production was evaluated using 
antibodies against MMP-2, MMP-13 and MT1-MMP. Both MMP-2 and 
MMP-13 were detected from the cell culture media of MG-63 cells before and 
after clodronate treatment. The antibody for MMP-13 did not detect MMP-
13 protein in human MG-63 osteosarcoma cells. Using specifi c polyclonal 
antibody for MT1-MMP was seen the presence of MT1-MMP in cell lysates of 
sizes 56/62 kDa. Additional 56/62 gelatinolytic bands could also be detected 
in zymograms.
4.6. Immunofl uorescent staining of MT1-MMP in 
osteosarcoma cell monolayers (II).
Immunofl uorescent cytochemistry of the MG-63 cell line for MT1-MMP was 
performed using mouse anti-human MT1-MMP monoclonal antibody, followed 
by fl uorescein-conjugated rabbit anti-mouse IgG. We found that MT1-MMP 
was distributed at the cell surface in MG-63 cells treated with PMA. Incubation 
with 0, 0.1 mM and 1.0 mM clodronate dose-dependently decreased the steady-
state pericellular expression of MT1-MMP immunoreactivity.
4.7. Clodronate inhibits the activity of catalytic domain of 
human recombinant MT1-MMP (II).
Clodronate in the concentration range of 0 to 2.0 mM inhibited the activity of 
the catalytic domain of human recombinant MT1-MMP. The IC50 was found to 
be 40 to 70 µM. The ability of 400 µM clodronate to inhibit MT1-MMP was 
reduced in the presence of high (5mM) Ca2+ concentration in the assay buffer 
when compared to physiological (1 mM) Ca2+ concentration.
4.8. Selection and early characterization of 
MMP-9-binding peptide (III)
The CTTHWGFTLC (abbreviated CTT1) peptide is one of three 
(CRRHWGFEFC, CTTHWGFTLC, CSLHWGFWWC) ten-amino-acid 
sequences found by panning of CX9 library against MMP-9. All the peptides 
found have a conserved HWGF sequence and cysteines at both ends forming 
a circular peptide when oxidized. The CTT1 and CRRHWGFEFC inhibited 
gelatine degradation by MMP-9 and MMP-2 at low micromolar concentrations. 
CTT1 peptide was chosen after a more detailed investigation because of its more 
favourable solubility. The importance of cyclizations was tested by creating an 
analogue of the CTT1 peptide that had serines at the ends instead of cysteins. 
This linear STTHWGFTLS peptide lacked almost completely the inhibition 
4. RESULTS
225239 Heikkila_2205.indd   Sec1:53 5/22/05   21:20:15
54
activity of CTT1. CTT1 did not inhibit other members of the MMP family or 
other classes of proteinases. 
4.9. Inhibition of cell migration by CTT1 (III).
CTT1 inhibited migration of HT1080 fi brosarcoma, C8161 melanoma, SKOV-3 
ovarian carcinoma, KS1767 Kaposi’s sarcoma, Eahy 926 and HUVEC endothelial 
cells in a dose-dependent manner (20-500 µM). The maximal inhibition (80%) 
was seen at a peptide concentration of 500 µM. Matrigel invasion of HT1080 and 
C8161 cells was also suppressed by the CTT1. Maximal inhibition was 90% at 
500 µM, the highest concentration studied. None of the control peptides affected 
migration or invasion. CTT1 was not toxic to the cells, as cell viability did not 
decrease even when the cells were cultured as long as two days in the presence of 
the peptide. Initial attachment and spreading of the cells on fi bronectin, collagen 
type IV, or Matrigel substrata was not affected by the peptide.
4.10. Prevention of tumourigenesis and inhibition of 
tumour growth in mice (III).
MDA-MB-435 breast carcinoma cells were preincubated with CTT1 (100 µg) 
or vehicle alone (DMEM) and injected subcutaneously into nude mice. CTT1 
delayed formation of tumours (follow-up time was 5 weeks), and the tumours 
that arose were signifi cantly smaller than those in the control group. 
MDA-MB-435-derived breast carcinomas were established in the mammary 
fat pad nude mice. CTT1 (200 µg per mouse) or a control peptide was injected 
into the subcutaneous tissue adjacent to the tumour three times a week for three 
weeks. The volumes of tumours treated with CTT1 remained stable, whereas the 
tumours treated with the control peptide progressed, reaching up to fi ve times 
the initial volume at the end of the experiment.
Mice bearing established KS1767-derived Kaposi’s sarcomas were injected 
intraperitoneally with CTT1 (100 µg/mouse) or control peptide three times a 
week for four weeks. KS1767-derived Kaposi’s sarcomas grew more slowly in mice 
treated with intraperitoneal injections of CTT1 than in the control mice treated 
with the vehicle alone. In addition, establishment and growth of SKOV-3-derived 
ovarian carcinomas was also inhibited when CTT1 (200 µg) was coinjected with 
the cells into the peritoneal cavity of severe combined immune-defi cient (SCID) 
mice. CTT1 increased the survival of the mice bearing SKOV-3 tumours as 
compared with the control group, which received a control cyclic peptide. 
Similarly, the survival of SCID mice bearing i.p. SKOV-3 tumours also improved 
upon treatment with CTT1. In two independent experiments, four out of six 
and three out of fi ve of the peptide-treated mice were alive at the time when all 
the control mice had died from their tumour burden.
4.11. Targeting of CTT1 phage into tumours (III).
CTT1 sequence-containing phages were inserted intravenously to mice bearing 
size-matched KS1767-derived Kaposi’s sarcoma tumours (approximately 
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1,000 mm3) and recovered after perfusion. Tumour homing ability of the phage 
was elevated ten-fold compared to phage having random peptide sequence. The 
tumour- to brain-ratio was also approximately ten-fold. Moreover, the homing 
of the CTT1 phage into the tumours was specifi c, as it could be substantially 
inhibited upon coinjection of the cognate peptide (CTT1). Coinjection of an 
unrelated cyclic peptide (CARAC) had no appreciable effect.
4.12. The effect of CTT1 and CTT2 peptides on 
pro-MMP-9 conversion and gelatinolytic activity of 
the cultured HSC-3 tongue carcinoma cells (IV).
The serum-free HSC-3 conditioned medium revealed that  hydrophobic CTT1 
and it’s newly developed derivative hydrophilic GRENYHGCTTHWGFTLC 
(abbreviated CTT2) peptides at concentrations from 20 to 100 µg/ml markedly 
reduced the 92 kDa pro-MMP-9 conversion to 77-82 kDa active forms in 
gelatin zymography. CTT2 did not affect the level of conversion of MMP-2. 
We also studied the effect of the peptides on the catalytic activities of secreted 
gelatinases using the iodinated gelatin degradation assay. CTT1 and CTT2, at 
concentrations of 20, 50 and 100 µg/ml, decreased the activity of conditioned 
media gelatinase to 58% and 75% (SD: ± 1.4% and ± 4.2%), 42% and 54% (SD: 
± 8.5% and ± 11.3%) and 29% and 24% (SD: ± 5.7% and ± 24.0%), respectively. 
Furthermore, the RPA analysis of various concentrations (20, 50 and 100 µg/
ml) of CTT1 and CTT2 peptides showed no effect on the MMP-9 mRNA 
expression levels of HSC-3 cells.
4.13. The effects of CTT1 and CTT2 peptides on HSC-3 
cell fi bronectin adhesion, proliferation, viability, migration 
and invasion in vitro (IV).
At a concentration of 100 µg/ml, CTT2 partially decreased the viability of HSC-
3 cells during a 24-h culture period, but did not affect the cells at the 50 or 20 
µg/ml concentrations. There was no effect on cell viability by CTT1 with the 
concentrations used. HSC-3 cell proliferation and cell adhesion on fi bronectin 
were not affected by CTT1 or CTT2 at a 100 µg/ml concentration. 
The CTT1 and CTT2 peptides at 20, 50 and 100 µg/ml concentrations 
effi ciently and dose-dependently inhibited the random migration and the in vitro 
invasion of human tongue HSC-3 cells through Matrigel cell culture inserts (see 
Table 3). The control C1 peptide had no effect on cell migration and invasion 
at a concentration of 100 µg/ml. CTT2 was signifi cantly more effective than 
CTT1 in both assays (P ≤ 0.024). 
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Table 3. Inhibition (%) of HSC-3 cell migration and invasion with CTT1 and 
CTT2.
n = 3, p ≤ 0.05
HSC-3 cells Migration
20      50     100µg/ml
Invasion
20      50     100µg/ml
CTT1
CTT2
38%    51%    66%
43%    68%    73%
25%    34%    54%
28%    59%    69%
4.14. Inhibition of tumour growth and angiogenesis by 
CTT2 in mice (IV).
The effect of the CTT2 peptide on tumour growth in vivo was analysed by 
injecting HSC-3 tongue carcinoma cells subcutaneously into athymic mice, 
followed by beginning the peptide injections three days after. CTT2 (400 µg), 
the control peptide (C2 peptide, 400 µg) or PBS were injected intravenously 
once a day for fi ve days. The growth of the tumours treated with CTT2 was slow, 
whereas the tumours treated with C2 or PBS gradually progressed, reaching 
up to fi ve times the initial volume at the end of the experiment. Furthermore, 
the tumours treated with CTT2 faded and tumour size was reduced. CTT2-
injections signifi cantly (P ≤ 0.012) increased the survival of the mice. After 
one month all the mice treated with C2 or PBS had succumbed to the disease, 
whereas one-third of the CTT2-injected mice were alive after two and a half 
months. There was no difference in tumour growth and survival between the 
genders. We also examined the effect of CTT2 on the angiogenesis in female and 
male mice bearing human tongue SCC tumours by immunodetection of cells 
expressing the endothelial cell marker FVIII. Immunohistochemical analysis 
of the tumours revealed that the blood vessel density was signifi cantly lower 
(P ≤ 0.043) in the CTT2 peptide group than in the C2 and PBS groups. All the 
tumour tissue sections were stained with CK-PAN to evidence that the tumours 
had originated from the carcinoma cells. Furthermore, we demonstrated the 
cell-matrix interactions by van Gieson histological staining. In the C2- and PBS-
treated groups the tumour cells were large, disordered, loosely orientated and 
surrounded by thin interrupted collagen fi bres, whereas in the CTT2-treated 
tumours the carcinoma cells remained mainly small and faded, and the tumours 
were surrounded by a continuous collagenous and fi brous capsules.
4.15. Inhibition of human tongue SCC tissue 
gelatinolytic activity by CTT1 and CTT2 as 
assessed by in situ zymography (IV). 
In human native tongue SCC tissue sections gelatinolytic activity could be 
clearly detected in the carcinoma cells and extracellular matrix. Gelatinolytic 
activity was almost completely abolished with 100 µg/ml of CTT1 or CTT2 
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peptide, whereas the control peptide (C1) did not affect the gelatinolytic activity 
of these carcinomas.
4.16. Recovering HSC-3 cells with immunomagnetic 
method and isolation and production of MMP-9 by HSC-3 
cells (unpublished data).
In the immunomagnetic method the mean recovery of the seeded HSC-3 cells was 
close to 46% (Table 4). Even in the experiments seeding only 10 cells the recovery 
always exceeded zero, being at least 4 captured carcinoma cells (Table 4). Each 
captured HSC-3 cell stained positively with the polyclonal MMP-9 antibody (not 
shown).
Table 4. Results of recovery experiments using the immunomagnetic method
         
Approximal number of seeded HSC-3 cells in 2x107 
MNCs
 0 10 100 1000
Range (n=8) 0 4-30 23-116 120-790
Mean recovery 0 17 91 401
Standard deviation 0 9,23 36,07 268,14
Each experiment was performed 8 times. The values in the boxes show the 
range of cell numbers recovered, the mean recovery and the standard deviation 
for each number of seeded HSC-3 cells.
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5. Discussion 
Since the discovery of the fi rst archetypal MMP (MMP-1) over four decades 
ago by Gross and Lapierre (1962), most major pharmaceutical companies have 
had MMP inhibitor programmes for a variety of tissue destructive diseases. 
During decades of intensive research, tens of thousands of compounds have been 
synthesized and screened as potential MMP inhibitors, and large amounts of 
money have been spent on in vitro and in vivo studies as well as on clinical trials. 
So far, to date, Periostat (doxycycline hydrate, a tetracycline analogue) is the 
only MMPI licensed in the United States, and the application is for periodontal 
disease (Wynn 1999). In the targeting of MMPs for cancer therapy, it is important 
to recognize that these proteases are mainly expressed by surrounding stromal 
fi broblasts, vascular cells, and by the infl ammatory cells infi ltrating tumours, 
rather than by the cancer cells themselves (Bissell and Radisky 2001). 
5.1. The lack of effi cacy of MMPIs in cancer treatment
Why are MMPIs not effective in clinical trials in cancer treatment despite 
abundant proof-of-concept in vitro and in vivo studies? Most clinical trials of 
MMPIs have yielded disappointing results, perhaps due to inappropriate study 
design or tumour staging, or to lack of selectivity of broad-spectrum MMPIs used, 
and to old ways of thinking that MMPs only degrade ECM, without realizing 
that MMPs also infl uence various non-matrix substrates (Coussens et al. 2002, 
Overall and Lopez-Otin 2002, Peterson 2004). Firstly, MMPI clinical trials 
have typically targeted late-stage cancer patients while most preclinical studies 
manipulated MMP activity prior to the induction of cancer. Animal experiments 
show that MMPs should be targeted early in the cancer progression. Batimastat 
reduces endpoint tumour burden in an animal model of progressive pancreatic 
carcinoma if given at the early hyperplastic stage, but the effects are limited if 
treatment begins at later stages (Bergers et al. 1999). Secondly, classical animal 
models of subcutaneous or intravenous injection of human tumour cells into 
immunodefi cient mice are insuffi cient to evaluate the activity of cytostatic 
agents such as MMPIs because they do not adequately recapitulate host-tumour 
interactions (Peterson 2004). Malignant cells are genetically highly unstable so 
therapies targeting these cells can result in modifi cations resulting in resistance 
to cancer therapy. MMP activity in cancers usually originates from both tumour 
and stroma and importantly, stromal cells are much less likely to develop drug 
resistance (McCawley and Matrisian 2000). Thirdly, certain MMPs can have 
dual effects on cancer development (Andarawewa et al. 2003), or some functions 
of MMPs might help defy cancer (Balbin et al. 2003, Hamano et al. 2003, 
Pozzi et al. 2002). Furthermore, these MMPIs may also target other proteases, 
such as the ADAMTSs, which have the ability to slow down tumour growth 
through their antiangiogenic activity (Vazquez et al. 1999). Therefore it might 
be important to target better specifi c MMPs or specifi c functions of MMPs. 
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Fourthly, the dosage used in some trials could, however, also have been too 
low because of the side effects of MMPIs: the most commonly MMPIs cause 
musculoskeletal pain, which is evidently due to the inhibition of sheddases. 
Sheddases are responsible for release of membrane-bound proteins, including 
TNF-α.
There is no reliable biomarker in phase I studies, which could serve as a 
guide for dose-selection and administration schedule for phase II. As known 
for CMTs, application of the drug during activation of MMPs in vitro drops 
IC50s dramatically in comparison to adding the drug after activation (Golub et 
al. 1998). Biomarkers may not only be valuable in helping us understand how 
to derive optimal biological dose and dosing schedule, but may also be used in 
in vitro and in vivo studies to defi ne target identifi cation. For example, MMP-
11 and -14 expression levels are negative prognostic indicators in small-cell lung 
cancer, and this type of tumour has undetectable expression of MMP-2 (Michael 
et al. 1999). Tanomastat, which targets MMP-2 but lacks MMP-11 inhibitory 
activity, may not be the best choice for this type of cancer. In fact, tanomastat 
treatment accelerated mortality in patients with pancreatic and small-cell lung 
cancer, which lead to the withdrawal of this drug for both arthritis and cancer 
treatment (Peterson 2004). Analysis of the serum or plasma levels of MMPs has 
been largely uninformative (Hidalgo and Eckhardt 2001).
MMPIs are cytostatic rather than cytotoxic, so conventional measures of 
effi cacy such as reduction in tumour size, could not be used to monitor drug 
activity. Thus they do not directly cause shrinkage of established tumours. Phase I 
trials were often followed immediately by phaseII/III combination trials without 
the benefi t of effi cacy information from smaller studies (Peterson 2004).
5.2. Use of MMP inhibiting bisphosphonates in 
cancer treatment
Evidence has been accumulated from in vitro and in vivo studies that 
bisphosphonates can directly affect tumour cells. They can induce tumour cell 
death, for example by inducing cell apoptosis or inhibit their growth and spread. 
They may also indirectly reduce cancer growth by cutting-off their ’survival 
factors’ such as TGF-β and IGF-I, which are often released from the resorbing 
bone. Based on these effects they may represent a new and alternative class of 
drugs with antitumour power (Green 2003). 
Bisphosphonates directly inhibit the activity of MMPs, which is obligatory 
for successful down-regulation of tumour cell invasion. The mechanisms 
of MMP inhibition evidently involve the ability of bisphosphonates to act as 
cation chelators, as demonstrated in our studies showing that pamidronate and 
zoledronate inhibited dose-dependently MMP-12 and MMP-20. Alendronate, 
pamidronate and zoledronate inhibited MMP-8, -3 and -13 and alendronate 
and clodronate inhibited MMP-1, -2, -3, -8, -9, -13 and 14 (I, II). Other studies 
confi rm and further extend our results; e.g. tiludronate inhibits MMP-1 and 
MMP-3, and clodronate inhibits MMP-8 and MMP-1 (Nakaya 2000, Teronen 
et al. 1997a, b, Boissier et al. 2000). Alendronate inhibited the invasion of 
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fi brosarcoma and melanoma cells (I) similarly to breast and prostate cancer cells 
through artifi cial membrane in vitro as published by Boissier et al. 2000. This is 
thought to be due, at least in part, to the inhibitory effect of bisphosphonates on 
MMPs. However, the specifi c inhibition of distinct MMPs seems to differ with 
various bisphosphonates. Certain bisphosphonates also exhibit effects on MMPs 
production by cancer cells. Valleala et al. (2003) have shown that monocytes/
macrophages MMP-9 mRNA levels remain relatively stable in the presence of 
clodronate, but in contrast, pamidronate increases mRNA levels even up to 10-
fold. However, clodronate dose-dependently down-regulated, but pamidronate 
up-regulated MMP-9 secretion at lower concentrations. In contrast, using 
higher concentrations of pamidronate MMP-9 secretion decreases (Valleala 
et al. 2003). Zoledronic acid causes a signifi cant reduction in MMP-7 levels 
and an even greater proportionate increase in the levels of its inhibitor TIMP-2 
in prostate cancer cells in bone marrow stroma co-cultures (Montague et al. 
2004). On the other hand, Denoyelle et al. (2003) did not see an increase 
in MMP-2 and -9 levels at the 1 µM zoledronic acid concentrations in breast 
cancer cells. In our studies, clodronate inhibited PMA-induced proteolytic 
activation of proMMP-2 by human osteosarcoma cells (II). Furthermore, 
clodronate also downregulated expression of MT1-MMP mRNA and protein 
production in human osteosarcoma cells and inhibited MT1-MMP activity (II). 
Thus intracellular mechanism involves downregulation of induced MT1-MMP 
mRNA and protein expression (II). These fi ndings may, at least in part, explain 
the antitumour activities of clodronate at molecular level. We did not see any 
effect of alendronate on fi brosarcoma and melanoma cell adhesion (I) similarly 
to Riebeling et al. (2002), who analysed clodronate in melanoma cell adhesion. 
However, there are studies demonstrating that bisphosphonates exert effects on 
cancer cell adhesion (Brown et al. 2004). 
In our study, alendronate clearly inhibited the migration of human umbilical 
vein endothelial cells (I). Other studies confi rm that bisphosphonates can inhibit 
angiogenesis, that is essential to tumour growth and metastases (Giraudo et 
al. 2004). Zoledronic acid suppressed MMP-9 expression in a mouse model 
involving human cervical cancer by infi ltrating macrophages and inhibited 
metalloproteinase activity, reducing association of VEGF with its receptor on 
angiogenic endothelial cells (Giraudo et al. 2004). Zoledronic acid was found 
to be antiangiogenic, producing effects comparable to MMP-9 gene knockout 
mice in impairing angiogenic switching, progression of premalignant lesions 
and tumour growth. Zoledronic acid therapy increased neoplastic epithelial 
and endothelial cell apoptosis without affecting hyperproliferation, indicating 
that zoledronic acid was not antimitotic (Giraudo et al. 2004). Furthermore, 
zoledronate sensitizes endothelial cells to TNF-induced programmed cell death 
(Bezzi et al. 2003).
On the other hand, 0.0001-10 µM alendronate inhibits invasion of PC-3 
prostate cancer cells by affecting the mevalonate pathway, but alendronate had 
no effects on the levels of MMP-2 or MMP-9 activity accumulated during the 
invasion assay (Virtanen et al. 2002). 
The mechanism of MMP inhibition remains a matter of speculation, although 
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it is possible that it is linked to the primary inhibition of the mevalonate pathway 
and Ras inactivation. Inhibition of the Ras/Rho/MAPK pathway, linked 
through the mevalonate pathway, is known to inhibit MMP production in some 
tumour cell types (Shin et al. 2002), and inhibition of Ras in vitro will also block 
the production of MMPs (Futamura et al. 2001). These fi ndings suggest that 
bisphosphonates may be useful agents for the prophylactic treatment of patients 
with cancers that are known to metastasize preferentially to bone.
However, doctors in the USA have during the past few years met a cluster of 
patients treated with bisphosphonates suffering from necrotic lesions in the jaw. 
The typical presentation is a non-healing tooth-extraction socket or exposed 
jawbone, and the clinical outcome was similar to osteoradionecrosis. The 
pathogenesis of jaw lesions may be related to potent osteoclastic inhibition, altered 
blood fl ow in bone, or localized antiangiogenesis by bisphosphonate medication 
(Ruggiero et al. 2004). Bagan et al. (2005) present a series of ten patients with 
osteonecrosis of the jaw that appeared following cancer chemotherapy without 
evidence of metastatic disease to the jaws. All the patients had received treatment 
for their malignant bone disease with bisphosphonates.
The fact that bisphosphonates have been used clinically for a number of 
years and are well known both pharmacologically and toxicologically suggests 
that they should be investigated in properly designed studies in patients with 
cancer for which inhibition of MMPs might be benefi cial. Detailed knowledge 
of MMP inhibition spectrum of the bisphosphonates used and the identifi cation 
of protease profi les of each patient’s tumour, will enable us to develop targeted 
therapies with reduced toxicities. These clinical observations and preclinical 
evidence of antitumor activity of bisphosphonates provide a compelling basis to 
study further their antineoplastic effi cacy in cancer patients. We need further 
research to fully elucidate the molecular mechanism involved and to determine 
the most effective dose and medication schedule of bisphosphonates to maximize 
their antitumour potential in the clinical setting, either alone or in combination 
with standard antineoplastic agents or other anti-MMP drugs (Llavaneras et al. 
2001, 1999). 
5.3. Novel approaches for MMP inhibition in cancer
Clinical trials have so far focused on patients with advanced-stage disease. Based 
on animal experiments, we would expect that the clinical effi cacy might be 
improved either by using MMPIs in the treatment of early stages of the disease 
(in combination with conventional therapy), or as preoperative and postoperative 
treatment to prevent micrometastatic spread and recurrence of the disease. Thus 
the best therapeutic window for the MMPIs may be lost if the disease cannot be 
diagnosed early enough. Oral cancer, which is aggressive and has a high potential 
for invasiveness associated with high mortality, is often diagnosed in an advanced 
stage. The fi ve-year survival rate of early-stage oral cancer is approximately 80%, 
while the survival drops to 19% for late-stage disease, and the rate of second primary 
tumour development in these patients has been reported to be 3-7% per year, higher 
than for any other malignancy (Murphy et al. 1995, Day and Blot 1992). 
5. DISCUSSION 
225239 Heikkila_2205.indd   Sec1:61 5/22/05   21:20:21
62
Endothelial cells, migrating tumour cells and infl ammatory cells in the near 
proximity of tumours secrete gelatinases in a manner that corresponds to poor 
prognosis in cancer. For example, it is known that the expression of MMP-9 
is a negative prognostic indicator for head and neck squamous cell carcinoma 
(Ruokolainen et al. 2004). These fi ndings highlight the need for synthetic 
MMPIs that would selectively target specifi c MMPs. Our group created the 
cyclic, hydrophobic decapeptide (CTT1), which is the fi rst gelatinase-selective 
peptide inhibitor (III). Thereafter we generated the hydrophilic, derivative of 
the peptide (CTT2) having a GRENYHG-tail (IV). In this study (III, IV) 
these peptides (CTT1 and CTT2) were found to inhibit the gelatinolytic activity 
of MMP-2 and MMP-9, but not that of other MMPs or serine proteinase 
(human neutrophil elastase, neutrophil cathepsin G and tumour-trypsin-2), 
cell migration and invasion of various tumour cells in vitro, as well as tumour 
progression in vivo in mouse models, indicating the importance of gelatinases 
(MMP-2 and MMP-9) in tumour invasion. However, the exact mechanism 
how CTT1 and CTT2 inhibit gelatinase activity is not completely known (III, 
IV), but the hydrophilic CTT2 was shown to be a slightly better inhibitor than 
hydrophobic CTT1 in vitro (IV). CTT1 exhibited strong tumour-homing 
ability in comparison to the normal tissues (III). This knowledge could guide 
the selection of a more appropriate tumour types for the clinical testing of CTT1 
or CTT2, which target MMP-2/MMP-9 and have very little activity toward 
other MMPs (III, IV). 
Both CTT1 and CTT2 peptides can be easily degraded in vivo, restricting their 
oral availability. The targeting capability of CTT1 was further demonstrated with 
liposomes coated with the CTT1 peptide. Hydrophobic CTT1 combined with 
adriamycin-containing liposomes enhanced up to 4-fold the killing of leukaemia 
and sarcoma cells compared to the control liposomes without the peptide. CTT1 
has also been used for the delivery of anti-cancer drugs to tumours, based on 
its ability to home to tumours expressing MMP-2 and MMP-9 (Medina et al. 
2001). CTT1 is thus not only a potential anti-cancer compound per se due 
to its selective gelatinase inhibitory activity, but it can also be used as a tool 
for more targeted delivery of other anti-cancer drugs as well as gene delivery 
(Medina et al. 2005). In this way, the development of more specifi c MMPIs may 
also indirectly have benefi ts in the treatment of cancer patients. In the future it 
would be important to analyse the effectiveness of hydrophilic CTT2-bearing 
liposomes containing a cytostatic drug to selectively target and kill the tumour 
cells and neo-vessels by targeting the site of MMP-9 action.
The evaluation of MMPIs in immune-defi cient mice transplanted with 
human tumours is the major model system for drug development. This model 
allows rapid and quantifi able assessment of antitumour activity relative to mouse 
toxicity. However, these kind of preclinical studies do not accurately predict 
human effi cacy. The organotypic gel culture system, which is generated by plating 
tumour cells on to a synthetic stroma composed of a collagen gel embedded with 
fi broblasts, allows carcinoma cells to grow in a 3D state. This model stimulates 
the tumour-stroma interaction and recapitulate more closely the in vivo situation 
(Nyström et al. 2005). 
The identifi cation of the specifi c proteases that must be targeted in cancer 
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should also be correlated with the design of synthetic MMPIs that selectively 
reduce the binding and cleavage of certain substrates by the protease, while not 
interfering with the cleavage of others. For this purpose, it is essential to increase 
the number of 3D structures available for these enzymes, as well as to identify 
the in vivo substrates that individual MMPs can target alone or in co-operation 
with other proteolytic systems, the hydrolysis of which may strongly infl uence 
the behaviour of tumour cells. In addition, a better understanding of the 
regulatory mechanisms that control individual MMP transcription, activation 
and inhibition may offer innovative strategies for targeting MMPs in cancer. 
These basic studies together with clinical improvements, such as introduction 
of imaging technologies for in vivo detection of MMPs (Medina et al. 2005), 
identifi cation of surrogate markers to monitor MMP inhibition (Mäntylä et 
al. 2003, Emingil et al. 2004a, b), and design of appropriate combinations 
of MMPIs with cytotoxic and other anti-MMP drugs (Llavaneras et al. 1999, 
2001), may fi nally lead to effective MMPI-based therapies for cancer (Overall 
and Lopez-Otin 2002). 
One of the major questions is whether the MMPs in general are a clinically 
relevant target for the therapeutic intervention in cancer, and to what extent 
other tissue destructive diseases could be treated with the broad-spectrum 
MMPIs. Although over a hundred small-molecules targeting the catalytic site 
of the MMPs, have been synthesized, these broad-spectrum MMPI-compounds 
have limited specifi city to individual MMPs and to date no signifi cant success has 
been seen with these compounds in clinical trials. At present, suffi cient or specifi c 
knowledge of the role of individual MMPs in cancer or other tissue-destructive 
diseases is lacking. Clearly, the function of MMPs is only now emerging. Hence, 
the decision as to which individual MMP should be targeted still remains an 
educated guess. Even if such knowledge were available, the conserved structural 
features of the MMPs indicate that it will be a considerable challenge to synthesize 
an active-site inhibitor with the selective specifi city to a single MMP. 
It remains to be seen whether the more selective active-site inhibitors, exosite 
inhibitors and inhibitors of protein-protein interactions such as those identifi ed 
in this study (III, IV), appear to be any more successful as cancer therapeutics. A 
better understanding of both the destructive (Kähäri and Saarialho-Kere 1999, 
Sorsa et al. 2004) and the defensive (Balbin et al. 2003, Owen et al. 2004) 
roles of MMPs in cancer progression is certainly required in order to achieve 
the use of MMPI as cancer therapeutics (Overall and Lopez-Otin 2002). The 
recent fi nding that MMP-2 interacts with the chaperone protein Hsp90 in the 
extracellular space and that this interaction regulates tumour cell invasion is one 
indication that we do not yet understand the details of tumour cell migration 
and invasion (Eustace et al. 2004). Furthermore, blocking MMPs alone may 
not be suffi cient to achieve an adequate clinical response. Hence, it is certainly 
worthwhile to consider the possibility of combination therapy with drugs 
affecting other functions of cancer cells. However, what has not been suffi ciently 
appreciated to date is that a minimal (but not excessive) activities and levels of 
these MMPs have physiological, anti-tumour and anti-infl ammatory properties 
by processing certain growth factors and anti-infl ammatory cytokines (Overall 
and Lopez-Otin 2002, Owen et al. 2004). In this regard, complete inhibition 
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of MMPs is not desired, but instead reduction of pathologically excessive MMP 
activities and levels should preferably be targeted (Sorsa and Golub 2005).
Taken together, these fi ndings emphasize the importance of defi ning the 
cancer degradome: the complete set of proteases produced by a specifi c tumour 
at a certain stage of development (Lopez-Otin and Overall 2002). This concept 
could be helpful to identify precisely the set of proteases that must be targeted 
in each specifi c situation, especially in light of the above-mentioned fi ndings 
demonstrating the occurrence of “protective” enzymes preventing tumour 
progression (Balbin et al. 2003). Nevertheless, bisphosphonates and the peptides 
identifi ed in this study as MMP inhibitors/down-regulators (I, II, III, IV) will 
hopefully be useful in addressing in more detail the role of MMPs in physiological 
and pathological conditions and to aid in the development of pharmacologically 
relevant and active agents to combat cancer and other diseases associated with 
pathologically excessive MMP activity.
5.4. The use of immunomagnetic method in detecting 
circulating tumour cells
Detection of circulating tumour cells and their MMP-9 expression in cancer 
patients can be useful in determining prognosis and monitoring systemic 
therapies. We used an immunomagnetic method to isolate, identify and quantify 
human tongue carcinoma cells from the peripheral blood mononuclear cell 
suspension. Circulating epithelial tumour cells are extremely rare and are present 
at a frequency of 1-10 in 106 cells, and thus this method was found to be very 
sensitive and specifi cally capable of detecting as few as one tongue carcinoma cell in 
2 x 107 in mononuclear cell suspension. Our results are comparable with the recent 
studies using immunomagnetic separation with various cancers (Werther et al. 
2000, Eaton et al. 1997, Kruger et al. 2000, Nakamura et al. 2000, Wirtschafter 
et al. 2002). The detection of circulating tumor cells as a tumour marker may 
be used to monitor tumour progression and to evaluate progression-free and 
overall survival of prostate and breast cancer patients (Ady et al. 2004, Gaforio 
et al. 2003, Soria et al. 1999, Luke et al. 1998). However, Marth et al. 2001 
reported that circulating tumour cells in the peripheral blood of patients with 
ovarian carcinoma did not predict prognosis. Furthermore, in a study analysing 
MMP-1, -2, -7 and -9 production in ten oral SCC patients by RT-PCR from 
laser-captured microdissection of cancer tissue and immunomagnetic separation 
of circulating cancer cells, only MMP-9 positive samples were detected (Ito et 
al. 2003). As we obtained promising results, we suggest that our study should 
be extended with long-term follow-up studies of cancer patients to investigate 
the primary tumour and circulating cancer cells and their MMP-9 expression in 
order to evaluate their prognostic value. The samples from cancer patients should 
be taken before surgical treatment; this helps to avoid detecting tumour cells 
which shed after surgical treatment from primary tumour. Therefore, we suggest 
that measurement of MMP-9 levels in primary tumours and micrometastases 
and the use of CTT1 or CTT2 for therapy might offer new strategies to combat 
cancer together with conventional surgery and radiation therapies. 
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6. Conclusions
1. Bisphosphonates are broad-spectrum MMP inhibitors and this inhibition 
involves cation chelation. Bisphosphonates further exert anti-metastatic, anti-
invasive and cell adhesion-promoting properties, which may prevent metastasis 
formation not only in hard tissues but in soft tissue as well in a dose-dependent 
manner.
2. Clodronate, at therapeutically attainable concentrations, dose-dependently 
directly inhibited the activity of the catalytic domain of human recombinant 
MT1-MMP, reduced the activation of proMMP-2 and down-regulated the 
expression of MT1-MMP mRNA and protein production by cultured MG-63 
human osteosarcoma cells, indicating that clodronate can reduce MT1-MMP 
RNA expression and activity.
3. In this study, we have discovered and initially characterized two novel peptides, 
CTT1 and CTT2, which target selectively and specifi cally gelatinases (MMP-2 
and MMP-9), inhibiting the gelatinase activities in many human carcinoma cell 
lines and endothelial cells in vitro and in vivo. These novel MMPIs may lead 
to a new treatment options of cancer in the future. The role and involvement 
of MMPs in pathological conditions demonstrates that the MMPIs are still 
attractive for drug development.
6. CONCLUSIONS
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